<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:112.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">REVIEW ARTICLE</span></p>
<p style="top:157.1pt;left:54.3pt;line-height:18.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:18.0pt">Are 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:12.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:18.0pt"> antagonists effective in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:18.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:18.0pt">compulsive disorder? A</span></p>
<p style="top:177.1pt;left:54.3pt;line-height:18.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:18.0pt">systematic review of literature</span></p>
<p style="top:214.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Daniele Serata</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1,2</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Georgios D. Kotzalidis</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">*, Chiara Rapinesi</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1,2</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Del</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">na Janiri</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Simone Di Pietro</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Gemma</span></p>
<p style="top:226.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Callovini</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Daria Piacentino</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Carlotta Gasperoni</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Roberto Brugnoli</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Vittoria Rachele Ferri</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Nicoletta Girardi</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">,</span></p>
<p style="top:238.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Roberto Tatarelli</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Stefano Ferracuti</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Gloria Angeletti</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">, Paolo Girardi</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1,2</span></sup><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> </span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and Antonio Del Casale</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1,3</span></sup></p>
<p style="top:257.4pt;left:54.3pt;line-height:6.4pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">1</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Neurosciences, Mental Health, and Sensory Organs (NeSMOS) Department, School of Medicine and Psychology, Sapienza University of</span></p>
<p style="top:269.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Rome, UOC Psychiatry, Sant</span><span style="font-family:AdvTT50a2f13e.I+20,serif;font-size:9.0pt">&#x2019;</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Andrea Hospital, Roma, Italy</span></p>
<p style="top:277.4pt;left:54.3pt;line-height:6.4pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">2</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Department of Neuropsychiatry, Villa Rosa Suore Ospedaliere of the Sacred Heart of Jesus, Viterbo, Italy</span></p>
<p style="top:287.4pt;left:54.3pt;line-height:6.4pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Department of Psychiatric Rehabilitation, P. Alberto Mileno Onlus Foundation, San Francesco Institute, Vasto, Chieti, Italy</span></p>
<p style="top:326.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt">Objective</span></p>
<p style="top:326.3pt;left:99.7pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">The purpose of this literature database search-based review was to critically consider and evaluate the</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:9.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">ndings of literature fo-</span></p>
<p style="top:336.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">cusing on ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:9.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">cacy and safety of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> antagonists in the treatment of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">compulsive disorder (OCD), so as to test whether preclinical</span></p>
<p style="top:346.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">data match clinical therapeutic trials.</span></p>
<p style="top:356.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt">Design</span></p>
<p style="top:356.3pt;left:89.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">The PubMed database has been searched for papers on 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> antagonists and OCD in humans and for animal models of OCD and</span></p>
<p style="top:366.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> receptors.</span></p>
<p style="top:376.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt">Results</span></p>
<p style="top:376.3pt;left:90.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Of the clinically tested 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> receptor antagonists, ondansetron has been used to treat OCD in</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:9.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">ve therapeutic studies, whereas</span></p>
<p style="top:386.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">granisetron only in one recent trial. Both showed some ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:9.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">cacy in open studies and superiority to placebo in double-blind studies, along with</span></p>
<p style="top:396.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">fair safety. No animal OCD model directly implicated 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> receptors.</span></p>
<p style="top:406.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt">Conclusions</span></p>
<p style="top:406.3pt;left:109.4pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Overall, results indicate some utility, but the available literature is too scanty to allow for valid conclusions to be drawn. The</span></p>
<p style="top:416.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">mismatch between animal models of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">compulsive disorder and clinical data with 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> antagonists needs more clinical data to en-</span></p>
<p style="top:426.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">sure that it is not an artefact. Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:447.3pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:9.0pt">key words</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2014;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">clinical trials as topic; models; animal; obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">compulsive disorder; serotonin 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:6.4pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> receptor antagonists; ondansetron;</span></p>
<p style="top:457.3pt;left:105.8pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">granisetron</span></p>
<p style="top:489.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">INTRODUCTION</span></p>
<p style="top:506.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">compulsive disorder (OCD) is severely dis-</span></p>
<p style="top:518.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">abling, with a 2</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">3% lifetime prevalence in the general</span></p>
<p style="top:530.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">population (Ruscio</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010). There is evidence for</span></p>
<p style="top:542.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">short-term but not long-term (Fineberg</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2013) ef-</span></p>
<p style="top:554.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy of higher doses than those used for depressive</span></p>
<p style="top:566.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and other anxiety disorders of clomipramine and selec-</span></p>
<p style="top:578.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tive serotonin (5-HT) reuptake inhibitor (SSRI) antide-</span></p>
<p style="top:590.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pressants (ADs) (Rabinowitz</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2008). Treatment</span></p>
<p style="top:602.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">resistance ranges from 30% to 57% (Katz</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990;</span></p>
<p style="top:614.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Ravizza</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1995; Newth and Rachman, 2001;</span></p>
<p style="top:626.7pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Ferr&#xe3;o</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007), stressing its pathophysiological</span></p>
<p style="top:489.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">complexity. The bulk of OCD treatment data points to</span></p>
<p style="top:501.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">drugs acting on serotonin (5-HT) bioavailability</span></p>
<p style="top:513.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(American Psychiatric Association, 2007).</span></p>
<p style="top:525.7pt;left:327.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst studies involving 5-HT in OCD date back to</span></p>
<p style="top:537.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the late 1960s, when clomipramine, the most speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">c</span></p>
<p style="top:549.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT transporter inhibitor among tricyclic antidepres-</span></p>
<p style="top:561.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sants (TCAs) (Fern&#xe1;ndez de C&#xf3;rdoba and L&#xf3;pez-Ibor</span></p>
<p style="top:573.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Ali&#xf1;o, 1967; L&#xf3;pez-Ibor, 1969; Insel</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1983),</span></p>
<p style="top:585.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">showed symptom improvement. With the advent of</span></p>
<p style="top:597.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the SSRIs,</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine,</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uvoxamine, paroxetine and ser-</span></p>
<p style="top:609.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">traline were tested and found to be effective in OCD</span></p>
<p style="top:621.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Goodman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1989; Jenike</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1989). Studies</span></p>
<p style="top:633.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of peripheral biomarkers of 5-HT metabolism in OCD</span></p>
<p style="top:645.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Hanna</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1991, 1995) and SSRI effectiveness</span></p>
<p style="top:657.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">support the involvement and dysfunction of 5-HT sys-</span></p>
<p style="top:669.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tems in OCD patients. Despite con</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">icting results</span></p>
<p style="top:681.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Lucey</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1992; Norman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1994), acute 5-HT</span></p>
<p style="top:693.7pt;left:317.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">stimulation might lead to OCD symptom worsening</span></p>
<p style="top:658.2pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">*Correspondence to: G. D. Kotzalidis, Sapienza University of Rome, Italy,</span></p>
<p style="top:667.2pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">School of Medicine and Psychology, Neurosciences, Mental Health and</span></p>
<p style="top:676.2pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Sensory Organs (NeSMOS) Department Sant</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Andrea Hospital, Via di</span></p>
<p style="top:685.2pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Grottarossa 1035-1039, 00189 Rome, Italy. Tel. 06-33775951; Fax: 06-</span></p>
<p style="top:694.2pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">33775342 E-mail: giorgio.kotzalidis@uniroma1.it</span></p>
<p style="top:732.6pt;left:483.6pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Received 15 July 2014</span></p>
<p style="top:742.6pt;left:463.7pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Accepted 12 December 2014</span></p>
<p style="top:742.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:57.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">human psychopharmacology</span></p>
<p style="top:68.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:11.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">84</span></p>
<p style="top:79.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">Published online 10 February 2015 in Wiley Online Library</span></p>
<p style="top:90.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">(wileyonlinelibrary.com)</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:10.0pt"> DOI</span><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">: 10.1002/hup.2461</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Monteleone</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1997; Broocks</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998; Mundo</span></p>
<p style="top:90.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1999). Furthermore, 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2C</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor stimulation</span></p>
<p style="top:102.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">with promiscuous serotonin agonists having stronger</span></p>
<p style="top:114.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nity for this receptor, like</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> m</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-chlorophenylpiperazine</span></p>
<p style="top:126.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(mCPP), worsened anxiety in healthy volunteers and</span></p>
<p style="top:138.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">compulsive symptomatology in OCD pa-</span></p>
<p style="top:150.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tients (Hollander</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1992). Terminal 5-HT presynap-</span></p>
<p style="top:162.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tic autoreceptor desensitisation following clomipramine/</span></p>
<p style="top:174.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">SSRIs might relate to long-term ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy of 5-HT-</span></p>
<p style="top:186.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">enhancing compounds in OCD (Blier and de Montigny,</span></p>
<p style="top:198.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">1998). In fact, compared with depression, longer treat-</span></p>
<p style="top:210.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ment (10</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">12weeks; Dougherty</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2004) and higher</span></p>
<p style="top:222.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">AD doses (El Mansari and Blier, 2006) are needed to</span></p>
<p style="top:234.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">obtain symptom improvement in OCD, matching the</span></p>
<p style="top:246.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">timeline of 5-HT autoreceptor desensitisation.</span></p>
<p style="top:258.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Dopaminergic involvement is suggested by D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> dopa-</span></p>
<p style="top:270.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mine receptor antagonist-induced improvement of com-</span></p>
<p style="top:282.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pulsive and behavioural Tourette symptoms (Goodman</span></p>
<p style="top:294.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990), clomipramine</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">s antidopaminergic activity</span></p>
<p style="top:306.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Austin</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1991), add-on D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonist effectiveness</span></p>
<p style="top:318.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(McDougle</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1994, 2000; Ramasubbu</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2000)</span></p>
<p style="top:330.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and animal</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ndings in the context of the psychostimu-</span></p>
<p style="top:342.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">lant model of OCD (Eilam and Szechtman, 2005).</span></p>
<p style="top:354.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Hence, from the 1990s onward, investigators focused</span></p>
<p style="top:366.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">on the role of dopamine (Choi, 2009) as an alternative</span></p>
<p style="top:378.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">or complementary neurochemical strategy to address</span></p>
<p style="top:390.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the complex pathophysiology of OCD.</span></p>
<p style="top:402.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Ineffectiveness of typical antipsychotic monother-</span></p>
<p style="top:414.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">apy in OCD (Denys</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2004) and OCD symptom</span></p>
<p style="top:426.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">induction by atypical antipsychotics with combined</span></p>
<p style="top:438.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">/5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor-blocking properties (Allen and</span></p>
<p style="top:450.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Tejera, 1994; Remington and Adams, 1994) support</span></p>
<p style="top:462.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">other pharmacological strategies, based on the interac-</span></p>
<p style="top:474.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion between serotonergic and dopaminergic systems.</span></p>
<p style="top:486.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">This view is supported by reduced 5-HT transporter</span></p>
<p style="top:498.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">density in the midbrain pons area along with increased</span></p>
<p style="top:510.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">dopamine transporter availability in OCD patients after</span></p>
<p style="top:522.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">citalopram treatment (Pogarell</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2005).</span></p>
<p style="top:534.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Serotonin 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors affect 5-HT, dopamine,</span></p>
<p style="top:546.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">noradrenaline, acetylcholine, gamma-aminobutyric acid</span></p>
<p style="top:558.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(GABA) and neuromodulator functions in the central</span></p>
<p style="top:570.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and peripheral nervous systems (Barnes</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990;</span></p>
<p style="top:582.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Martin</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1992; Huang</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2004; Choi</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:594.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2007; Fukushima</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009; Ortega</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012).</span></p>
<p style="top:606.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors in rodents are highest in the area</span></p>
<p style="top:618.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">postrema, solitary tract nucleus (Tecott</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1993;</span></p>
<p style="top:630.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Morales and Wang, 2002), neocortex, anterior olfactory</span></p>
<p style="top:642.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">complex, hippocampus, amygdala, striatum and nucleus</span></p>
<p style="top:654.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">accumbens (Morales</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998). The 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> subunit</span></p>
<p style="top:666.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">was supposedly the prevalent subtype, but recently, all</span></p>
<p style="top:678.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">neurons expressing it in the hippocampal CA1 area</span></p>
<p style="top:690.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and scattered cortical areas were found to express also</span></p>
<p style="top:702.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3B</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> subunit (Doucet</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007).</span></p>
<p style="top:78.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors are co-localised with GABA interneu-</span></p>
<p style="top:90.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rons in the ventral tegmental area (VTA), indirectly</span></p>
<p style="top:102.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">inhibiting cortical</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mesolimbic dopamine release (Bloom</span></p>
<p style="top:114.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and Morales, 1998; Chen</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2001). Localisation</span></p>
<p style="top:126.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in accumbal and amygdalar dopaminergic terminals</span></p>
<p style="top:138.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Morales</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998) prompts us to consider them as part</span></p>
<p style="top:150.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of the cortico-striatal-thalamo-cortical OCD circuitry</span></p>
<p style="top:162.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Del Casale</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2011).</span></p>
<p style="top:174.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Although much preclinical evidence points to a role</span></p>
<p style="top:186.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor in psychiatric disorders, 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span></p>
<p style="top:198.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">antagonists have been little used in their treatment.</span></p>
<p style="top:210.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Serotonin 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists, like ondansetron and</span></p>
<p style="top:222.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">granisetron, are worldwide prescribed, safe and effec-</span></p>
<p style="top:234.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tive antiemetic agents, mainly used in postsurgical</span></p>
<p style="top:246.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and antineoplastic drug-induced nausea and emesis.</span></p>
<p style="top:258.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Both selectively inhibit 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors (Butler</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:270.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">1988). However, they also antagonise weakly 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">4</span></p>
<p style="top:282.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">receptors (Miyata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1995; Hasler, 2009), whereas</span></p>
<p style="top:294.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron probably inhibits also other 5-HT receptor</span></p>
<p style="top:306.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">subtypes (Tonini, 2005) and granisetron appears to be</span></p>
<p style="top:318.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">more 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> selective (Blower, 1995). Having no</span></p>
<p style="top:330.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">appreciable af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nity for the GABA/benzodiazepine re-</span></p>
<p style="top:342.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ceptor complex, they have no sedative effects (Costall</span></p>
<p style="top:354.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990; Goodin and Cunningham, 2002) or poten-</span></p>
<p style="top:366.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tial for abuse, dependence, tolerance or withdrawal</span></p>
<p style="top:378.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">following abrupt discontinuation (Costall and Naylor,</span></p>
<p style="top:390.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">1992). A role for 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists in psychi-</span></p>
<p style="top:402.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">atric disorder treatment has been advanced since the</span></p>
<p style="top:414.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">early 1990s (Stefa</span><span style="font-family:AdvTT6120e2aa+01,serif;font-size:11.0pt">&#x144;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ski</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1992).</span></p>
<p style="top:426.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor activation has been found to increase,</span></p>
<p style="top:438.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists to reduce, anxiety-like</span></p>
<p style="top:450.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behaviour in animals (Costall and Naylor, 1992). The</span></p>
<p style="top:462.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">zacopride derivative (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">S</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">)-des-4amino-3-iodozacopride,</span></p>
<p style="top:474.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">which different from other benzoamides has a 200-fold</span></p>
<p style="top:486.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">preference for these receptors over the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">4</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors</span></p>
<p style="top:498.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1999), showed anxiolytic activity in the</span></p>
<p style="top:510.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mouse elevated plus-maze model of anxiety (Zhang</span></p>
<p style="top:522.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2001). 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonism may reduce threat</span></p>
<p style="top:534.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">perception, whose aberrant levels are a core feature of</span></p>
<p style="top:546.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD (Zhang</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2001). Postsynaptic 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> inhibi-</span></p>
<p style="top:558.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion decreases 5-HT turnover rate (Edwards</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:570.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">1996) and may relate to SSRI effectiveness in OCD.</span></p>
<p style="top:582.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Regarding the 5-HT</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">dopamine interplay in OCD,</span></p>
<p style="top:594.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> stimulation enhances dopaminergic activity</span></p>
<p style="top:606.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">when dopaminergic neurons are already hyperactive</span></p>
<p style="top:618.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Costall</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1987, 1990); however, other indirect in-</span></p>
<p style="top:630.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">teractions between the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor and the dopami-</span></p>
<p style="top:642.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nergic system are possible, and one of these involves</span></p>
<p style="top:654.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nicotinic acetylcholine receptor (nAChR) antagonism.</span></p>
<p style="top:666.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">In fact, nAChRs modulate dopaminergic transmission</span></p>
<p style="top:678.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Exley and Cragg, 2008), and antagonists may cross-</span></p>
<p style="top:690.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">react with 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors because of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">/nAChR</span></p>
<p style="top:702.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">structural similarity (Drisdel</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2008).</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">71</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:64.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Preclinical evidence suggests a role for 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> inhibi-</span></p>
<p style="top:90.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion in OCD treatment, mostly based on data of OCD an-</span></p>
<p style="top:102.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">imal models, which vary in their conception of OCD and</span></p>
<p style="top:114.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cover only partial aspects of human OCD-related behav-</span></p>
<p style="top:126.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">iour (Fineberg</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2011; Hoffman, 2011; Albelda and</span></p>
<p style="top:138.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Joel, 2012a, 2012b). In summary, the main pharmaco-</span></p>
<p style="top:150.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">logical models are quinpirole-induced and stimulant-in-</span></p>
<p style="top:162.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">duced stereotypies, 8-hydroxy-2-diisopropylaminotetral</span></p>
<p style="top:174.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ine (8-OH-DPAT)-induced and mCPP-induced reduc-</span></p>
<p style="top:186.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion in spontaneous or reinforced alternation and SSRI-</span></p>
<p style="top:198.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">induced reduction of rodent marble-burying behaviour</span></p>
<p style="top:210.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Albelda and Joel, 2012a). All these models encounter</span></p>
<p style="top:222.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">either face/content, construct or predictive validity prob-</span></p>
<p style="top:234.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">lems (Fineberg</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2011; Albelda and Joel, 2012a,</span></p>
<p style="top:246.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2012b); furthermore, they do not consider the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> re-</span></p>
<p style="top:258.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ceptor. However, ondansetron reversed anticholinergic-</span></p>
<p style="top:270.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">induced impairment in spontaneous alternation in the</span></p>
<p style="top:282.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">marmoset in one study (Barnes</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990) and attenu-</span></p>
<p style="top:294.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ated stimulant-induced stereotypy in the rat (Shankar</span></p>
<p style="top:306.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2000), whereas the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor has not been</span></p>
<p style="top:318.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">heretofore tested in the marble-burying paradigm. Com-</span></p>
<p style="top:330.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">bining these data, we may consider 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span></p>
<p style="top:342.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">involvement in OCD as possible.</span></p>
<p style="top:354.2pt;left:64.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Our aim was to review systematically the ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy</span></p>
<p style="top:366.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and safety of ondansetron and granisetron, the only</span></p>
<p style="top:378.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists that have received trials</span></p>
<p style="top:390.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in the treatment of OCD, either in monotherapy or as</span></p>
<p style="top:402.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">add-on/augmentation and at any dose, and to evaluate</span></p>
<p style="top:414.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">how these results match preclinical data.</span></p>
<p style="top:433.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">Design</span></p>
<p style="top:450.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">We conducted a PubMed search with no language or</span></p>
<p style="top:462.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">date</span></p>
<p style="top:462.2pt;left:82.4pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">limit</span></p>
<p style="top:462.2pt;left:112.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">with</span></p>
<p style="top:462.2pt;left:142.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the</span></p>
<p style="top:462.2pt;left:165.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">following</span></p>
<p style="top:462.2pt;left:218.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">search</span></p>
<p style="top:462.2pt;left:255.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">strategy:</span></p>
<p style="top:474.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(ondansetron OR Zofran OR granisetron OR Kytril</span></p>
<p style="top:486.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OR serotonin3 antagonist* OR 5-HT3 receptor* OR</span></p>
<p style="top:498.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5ht3* OR 5-ht3*) AND (obsessive* OR compulsive*</span></p>
<p style="top:510.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OR hoarding* OR washing OR ritual* OR OCD*</span></p>
<p style="top:522.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OR anxiety disorders OR tic disorder* OR Tourette*).</span></p>
<p style="top:534.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The last three keywords were included because OCD</span></p>
<p style="top:546.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">belongs to anxiety disorders in the Diagnostic and</span></p>
<p style="top:558.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Statistical Manual of Mental Disorders (DSM)-IV,</span></p>
<p style="top:570.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">whereas tic disorders and Tourette</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">s disorder often</span></p>
<p style="top:582.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">co-occur with OCD; however, we did not include any</span></p>
<p style="top:594.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">human study not speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cally focusing on OCD. All</span></p>
<p style="top:606.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">authors carried out searches under the guidance of</span></p>
<p style="top:618.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the corresponding author; all authors regularly met to</span></p>
<p style="top:630.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">discuss and compare their</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ndings and to decide which</span></p>
<p style="top:642.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">papers to include in the review; all interpretation was</span></p>
<p style="top:654.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">subjected to rounds of criticism and approval; consen-</span></p>
<p style="top:666.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sus was obtained when all members agreed.</span></p>
<p style="top:678.2pt;left:64.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The search yielded 152 papers as of [24 November</span></p>
<p style="top:690.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2014], most of which were loosely dealing with the role</span></p>
<p style="top:702.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and the pharmacological rationale of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span></p>
<p style="top:78.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">inhibitor treatment in OCD and related disorders. These</span></p>
<p style="top:90.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">papers were localised and obtained, and their references</span></p>
<p style="top:102.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">searched for possible other useful material. We then</span></p>
<p style="top:114.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">selected only those papers that used 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span></p>
<p style="top:126.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">antagonists to evaluate OCD symptoms in healthy</span></p>
<p style="top:138.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">controls or to treat patients with OCD for the clinical</span></p>
<p style="top:150.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">part of our review. Concerning the evaluation of the</span></p>
<p style="top:162.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">role of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor in animal models of OCD,</span></p>
<p style="top:174.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">we selected papers mentioning this receptor in their</span></p>
<p style="top:186.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">text. Papers were selected on the basis of their</span></p>
<p style="top:198.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">appropriateness, that is, publication in peer-reviewed</span></p>
<p style="top:210.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">journals; adequate description of aims and methods,</span></p>
<p style="top:222.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the latter being appropriate for reaching the aims;</span></p>
<p style="top:234.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">use of sound models in animals and adequate diag-</span></p>
<p style="top:246.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nostic systems for population inclusion in human</span></p>
<p style="top:258.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">studies (e.g. DSM-IV/IV-TR or International Classi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-</span></p>
<p style="top:270.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cation</span></p>
<p style="top:270.2pt;left:352.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of</span></p>
<p style="top:270.2pt;left:370.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Diseases</span></p>
<p style="top:270.2pt;left:416.6pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(ICD)-9/10);</span></p>
<p style="top:270.2pt;left:480.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">suf</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ciently</span></p>
<p style="top:270.2pt;left:537.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">long</span></p>
<p style="top:282.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">follow-up for effects of treatment to appear; the use of</span></p>
<p style="top:294.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">standardised scales to assess treatment effects (or</span></p>
<p style="top:306.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behavioural measures in animal paradigms); and the</span></p>
<p style="top:318.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">clear description of results. We did not refer to the</span></p>
<p style="top:330.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">DSM-5</span></p>
<p style="top:330.2pt;left:358.6pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(American</span></p>
<p style="top:330.2pt;left:413.2pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Psychiatric</span></p>
<p style="top:330.2pt;left:469.5pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Association,</span></p>
<p style="top:330.2pt;left:531.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2013;</span></p>
<p style="top:342.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Discussion), as studies with 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists focusing</span></p>
<p style="top:354.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">on the new conceptualisation of an OCD spectrum have</span></p>
<p style="top:366.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">still to appear in literature. Of all considered studies,</span></p>
<p style="top:378.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">only six were therapeutic trials (</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ve with ondansetron</span></p>
<p style="top:390.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and one with granisetron), and one was a one-dose</span></p>
<p style="top:402.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behavioural study with ondansetron (Table 1). Addi-</span></p>
<p style="top:414.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tional searches were focused on each of the main animal</span></p>
<p style="top:426.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">models of OCD (marble burying, acral lick dermatitis,</span></p>
<p style="top:438.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">spontaneous alternation, quinpirole-induced checking</span></p>
<p style="top:450.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behaviour,</span></p>
<p style="top:450.2pt;left:374.4pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">stimulant-induced</span></p>
<p style="top:450.2pt;left:463.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">stereotypies,</span></p>
<p style="top:450.2pt;left:528.2pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">8-OH-</span></p>
<p style="top:462.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">DPAT-induced and mCPP-induced reduction in sponta-</span></p>
<p style="top:474.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">neous or reinforced alternation) and the role of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span></p>
<p style="top:486.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">receptors, using simple wording and uniting the models</span></p>
<p style="top:498.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in one set through OR in PubMed (e.g. marble* OR</span></p>
<p style="top:510.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">quinpirole* OR acral* OR checking* OR spontaneous</span></p>
<p style="top:522.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">alternation OR (stimulant* AND stereotyp*) OR DPAT</span></p>
<p style="top:534.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OR 8-hydroxy-diisopropyl amino tetralin* OR mCPP</span></p>
<p style="top:546.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OR meta-chlorophenylpiperazine* OR reinforced alter-</span></p>
<p style="top:558.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nation), thereafter combining it with the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span></p>
<p style="top:570.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nd the intersection through AND (5-HT3* OR</span></p>
<p style="top:582.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5HT3* OR 5-hydroxytryptamine3* OR serotonin3*).</span></p>
<p style="top:594.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">This search yielded 294 items, the relevance of which</span></p>
<p style="top:606.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">was decided through repeated meetings of all authors.</span></p>
<p style="top:637.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">RESULTS</span></p>
<p style="top:654.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Animal models of OCD foresee no role for 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> re-</span></p>
<p style="top:666.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ceptor antagonists (only one study was found to be in-</span></p>
<p style="top:678.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">teresting among the 294 papers of the search string</span></p>
<p style="top:690.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">output but focused on the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor; Alkhatib</span></p>
<p style="top:702.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2013); however, evidence points to compatibility</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">72</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:704.5pt;left:40.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Table 1.</span></p>
<p style="top:669.2pt;left:40.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Summary of pharmacological trials of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor antagonists in OCD</span></p>
<p style="top:704.5pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Drug</span></p>
<p style="top:653.4pt;left:85.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Investigators,</span></p>
<p style="top:655.3pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">year (location)</span></p>
<p style="top:588.8pt;left:85.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Experimental</span></p>
<p style="top:577.9pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">design</span></p>
<p style="top:518.6pt;left:58.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Number, age</span></p>
<p style="top:527.8pt;left:67.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(years) and gender</span></p>
<p style="top:514.7pt;left:76.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of patients</span></p>
<p style="top:523.9pt;left:85.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receiving 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span></p>
<p style="top:515.8pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antagonists</span></p>
<p style="top:454.9pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Co-morbidities</span></p>
<p style="top:371.2pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Doses</span></p>
<p style="top:313.5pt;left:85.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Psychometric</span></p>
<p style="top:299.7pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tools</span></p>
<p style="top:221.6pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Results</span></p>
<p style="top:131.6pt;left:94.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Side effects</span></p>
<p style="top:704.5pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:657.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Broocks</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1998 (NIMH,</span></p>
<p style="top:657.0pt;left:130.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Bethesda,</span></p>
<p style="top:657.0pt;left:139.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Maryland,</span></p>
<p style="top:657.0pt;left:148.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">USA)</span></p>
<p style="top:600.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Double-blind single</span></p>
<p style="top:600.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">i.v. ondansetron</span></p>
<p style="top:600.0pt;left:130.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">versus placebo</span></p>
<p style="top:600.0pt;left:139.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">pretreatment</span></p>
<p style="top:600.0pt;left:148.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">followed by i.v.</span></p>
<p style="top:600.0pt;left:157.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mCPP, to test role</span></p>
<p style="top:600.0pt;left:166.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors</span></p>
<p style="top:600.0pt;left:175.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in OCD</span></p>
<p style="top:528.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">11 DSM-III-R</span></p>
<p style="top:528.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients,</span></p>
<p style="top:528.0pt;left:130.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">adults, 6 men and</span></p>
<p style="top:528.0pt;left:139.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5 women, mean</span></p>
<p style="top:528.0pt;left:148.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">age 39.1 &#xb1; 14.4,</span></p>
<p style="top:528.0pt;left:157.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">range 22</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">58</span></p>
<p style="top:461.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mild</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">moderate</span></p>
<p style="top:461.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">depression</span></p>
<p style="top:461.0pt;left:129.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(BDI</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 12</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2264;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 26)</span></p>
<p style="top:394.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">0.15 mg/kg</span></p>
<p style="top:394.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron once</span></p>
<p style="top:322.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">CPRS-OC, NOC,</span></p>
<p style="top:322.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">BDI</span></p>
<p style="top:255.0pt;left:112.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron did not</span></p>
<p style="top:255.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">counteract mCPP-induced</span></p>
<p style="top:255.0pt;left:130.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD symptoms</span></p>
<p style="top:158.0pt;left:112.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mCPP</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> anxiety, sweating,</span></p>
<p style="top:158.0pt;left:121.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nausea, drowsiness, tremor,</span></p>
<p style="top:158.0pt;left:130.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">yawning, and warm-skin</span></p>
<p style="top:158.0pt;left:139.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sensation unaffected by</span></p>
<p style="top:158.0pt;left:148.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron</span></p>
<p style="top:704.5pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:657.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2003</span></p>
<p style="top:657.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(Nashville,</span></p>
<p style="top:657.0pt;left:211.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Tennessee,</span></p>
<p style="top:657.0pt;left:220.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">USA)</span></p>
<p style="top:600.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">8-week open-label</span></p>
<p style="top:600.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron</span></p>
<p style="top:600.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">administration to</span></p>
<p style="top:600.0pt;left:211.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drug-free OCD</span></p>
<p style="top:600.0pt;left:220.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">patients</span></p>
<p style="top:528.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">8 DSM-IV OCD</span></p>
<p style="top:528.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">patients, mean age</span></p>
<p style="top:528.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">36.5 &#xb1; 5.9, 5 men</span></p>
<p style="top:528.0pt;left:210.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and 3 women,</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">16</span></p>
<p style="top:528.0pt;left:220.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS</span></p>
<p style="top:461.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4 GAD, 6 PD, 3</span></p>
<p style="top:461.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tic-like</span></p>
<p style="top:461.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mannerisms, 1</span></p>
<p style="top:461.0pt;left:211.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">dysthymic</span></p>
<p style="top:461.0pt;left:220.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder</span></p>
<p style="top:394.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3 mg/day</span></p>
<p style="top:394.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron, 3</span></p>
<p style="top:394.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">divided doses</span></p>
<p style="top:322.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS, HAM-</span></p>
<p style="top:322.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">D, HAM-A</span></p>
<p style="top:255.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron followed by</span></p>
<p style="top:255.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">28% drop of Y-BOCS</span></p>
<p style="top:255.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">scores from baseline (55%</span></p>
<p style="top:255.0pt;left:211.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in remitters) and remission</span></p>
<p style="top:255.0pt;left:220.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(at least 35% drop of Y-</span></p>
<p style="top:255.0pt;left:229.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">BOCS scores from baseline)</span></p>
<p style="top:255.0pt;left:238.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in 3 OCD patients (37% of</span></p>
<p style="top:255.0pt;left:247.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">total sample, 50% of</span></p>
<p style="top:255.0pt;left:256.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">completers); tic-like</span></p>
<p style="top:255.0pt;left:265.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mannerisms = positive</span></p>
<p style="top:255.0pt;left:274.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">predictor for response</span></p>
<p style="top:158.0pt;left:184.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Most frequent: 5</span></p>
<p style="top:158.0pt;left:193.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">constipation, 3 dry mouth,</span></p>
<p style="top:158.0pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and 2 headache; 2 dropouts</span></p>
<p style="top:158.0pt;left:211.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">at the 7th week for</span></p>
<p style="top:158.0pt;left:220.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">unspeci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ed reasons</span></p>
<p style="top:704.5pt;left:283.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:657.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2009 (Florence,</span></p>
<p style="top:657.0pt;left:301.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Italy)</span></p>
<p style="top:600.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">12-week</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt"> &#x2018;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">single-</span></p>
<p style="top:600.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">blind</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> (using blind</span></p>
<p style="top:600.0pt;left:301.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">rater to assess</span></p>
<p style="top:600.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">patient status)</span></p>
<p style="top:600.0pt;left:319.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">administration of</span></p>
<p style="top:600.0pt;left:328.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron to</span></p>
<p style="top:600.0pt;left:337.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment-resistant</span></p>
<p style="top:600.0pt;left:346.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients</span></p>
<p style="top:600.0pt;left:355.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">already treated</span></p>
<p style="top:600.0pt;left:364.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with antidepressants</span></p>
<p style="top:600.0pt;left:373.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(possibly</span></p>
<p style="top:600.0pt;left:382.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antipsychotics)</span></p>
<p style="top:528.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">14 treatment-</span></p>
<p style="top:528.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">resistant (at least</span></p>
<p style="top:528.0pt;left:301.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">20 on the Y-BOCS</span></p>
<p style="top:528.0pt;left:309.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">after</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">12-week</span></p>
<p style="top:528.0pt;left:319.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment with</span></p>
<p style="top:528.0pt;left:328.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">adequately dosed</span></p>
<p style="top:528.0pt;left:337.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">SSRIs or</span></p>
<p style="top:528.0pt;left:346.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">clomipramine)</span></p>
<p style="top:528.0pt;left:355.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">DSM-IV OCD</span></p>
<p style="top:528.0pt;left:364.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">patients, mean age</span></p>
<p style="top:528.0pt;left:373.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">42.2 &#xb1; 11.3, 8 men</span></p>
<p style="top:528.0pt;left:382.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and 6 women</span></p>
<p style="top:461.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mild depression</span></p>
<p style="top:461.0pt;left:291.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(MADRS</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 9</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2264;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 17)</span></p>
<p style="top:394.0pt;left:283.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Add-on ondansetron</span></p>
<p style="top:394.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">0.50 mg/day for</span></p>
<p style="top:394.0pt;left:301.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">rst 6 weeks to</span></p>
<p style="top:394.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1 mg/day until the</span></p>
<p style="top:394.0pt;left:319.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">12th week (SSRIs</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:394.0pt;left:328.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antipsychotics</span></p>
<p style="top:394.0pt;left:337.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">unchanged)</span></p>
<p style="top:322.0pt;left:283.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS,</span></p>
<p style="top:322.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">MADRS, CGI</span></p>
<p style="top:255.0pt;left:283.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:255.0pt;left:292.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">augmentation</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> treatment</span></p>
<p style="top:255.0pt;left:300.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">response (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">25% Y-BOCS</span></p>
<p style="top:255.0pt;left:310.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drop from baseline) in</span></p>
<p style="top:255.0pt;left:319.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">64.3% of OCD patients and</span></p>
<p style="top:255.0pt;left:327.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">remission (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">35% drop) in</span></p>
<p style="top:255.0pt;left:337.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">7.14%</span></p>
<p style="top:158.0pt;left:283.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mild</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">moderately decreased</span></p>
<p style="top:158.0pt;left:292.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">appetite, headache; no</span></p>
<p style="top:158.0pt;left:301.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">serious adverse event</span></p>
<p style="top:704.5pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:657.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2010 (Ahwaz,</span></p>
<p style="top:657.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Iran)</span></p>
<p style="top:600.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">8-week double-</span></p>
<p style="top:600.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">blind ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:600.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine versus</span></p>
<p style="top:600.0pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine</span></p>
<p style="top:528.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">20 DSM-IV-TR</span></p>
<p style="top:528.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients,</span></p>
<p style="top:528.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mean age 26 &#xb1;</span></p>
<p style="top:526.5pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2.76, 11 men and</span></p>
<p style="top:528.0pt;left:426.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">9 women,</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">21 Y-</span></p>
<p style="top:528.0pt;left:436.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">BOCS</span></p>
<p style="top:461.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Exclusion of</span></p>
<p style="top:461.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">psychiatric</span></p>
<p style="top:461.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorders,</span></p>
<p style="top:461.0pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">substance abuse,</span></p>
<p style="top:461.0pt;left:427.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">major physical</span></p>
<p style="top:461.0pt;left:436.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disease</span></p>
<p style="top:394.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 4 mg/</span></p>
<p style="top:394.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">day</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine</span></p>
<p style="top:394.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">20 mg/day</span></p>
<p style="top:394.0pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">combination</span></p>
<p style="top:322.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS</span></p>
<p style="top:255.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine</span></p>
<p style="top:255.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">combination associated with</span></p>
<p style="top:255.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">81.43% drop in Y-BOCS</span></p>
<p style="top:255.0pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">scores, compared with</span></p>
<p style="top:255.0pt;left:427.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">55.55% with</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:255.0pt;left:436.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span></p>
<p style="top:158.0pt;left:391.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">No signi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cant differences</span></p>
<p style="top:158.0pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">between ondansetron and</span></p>
<p style="top:158.0pt;left:409.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo; one dropout for</span></p>
<p style="top:158.0pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">severe headache with</span></p>
<p style="top:158.0pt;left:427.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron</span></p>
<p style="top:704.5pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Granisetron</span></p>
<p style="top:657.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2012 (Tehran,</span></p>
<p style="top:657.0pt;left:463.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Iran)</span></p>
<p style="top:600.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">8-week double-</span></p>
<p style="top:600.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">blind granisetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:600.0pt;left:463.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine versus</span></p>
<p style="top:600.0pt;left:472.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:600.0pt;left:481.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:528.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">20 DSM-IV-TR</span></p>
<p style="top:528.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients,</span></p>
<p style="top:528.0pt;left:463.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mean age 35.2 &#xb1;</span></p>
<p style="top:526.5pt;left:472.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">6.8, 6 men and 14</span></p>
<p style="top:528.0pt;left:480.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">women,</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">21 Y-</span></p>
<p style="top:528.0pt;left:490.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">BOCS</span></p>
<p style="top:461.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Exclusion of axis I</span></p>
<p style="top:461.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorders,</span></p>
<p style="top:461.0pt;left:463.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">substance abuse</span></p>
<p style="top:461.0pt;left:472.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and major physical</span></p>
<p style="top:461.0pt;left:481.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disease</span></p>
<p style="top:394.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Granisetron 1 mg</span></p>
<p style="top:394.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">q12h</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:394.0pt;left:463.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">100 mg/day</span></p>
<p style="top:394.0pt;left:472.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">combination for</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">rst</span></p>
<p style="top:394.0pt;left:481.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4 weeks, increased</span></p>
<p style="top:394.0pt;left:490.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">to 200 mg/day</span></p>
<p style="top:394.0pt;left:499.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">thereafter, with</span></p>
<p style="top:394.0pt;left:508.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">granisetron dose</span></p>
<p style="top:394.0pt;left:517.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">remaining unaltered</span></p>
<p style="top:322.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS</span></p>
<p style="top:255.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Granisetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:255.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">combination associated with</span></p>
<p style="top:255.0pt;left:463.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">60% drop in Y-BOCS,</span></p>
<p style="top:255.0pt;left:472.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compared with 35.36% of</span></p>
<p style="top:255.0pt;left:481.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine;</span></p>
<p style="top:255.0pt;left:490.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">furthermore, 100%</span></p>
<p style="top:255.0pt;left:498.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">complete response (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">35%</span></p>
<p style="top:255.0pt;left:508.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drop from baseline) and</span></p>
<p style="top:255.0pt;left:516.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">90% remission (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2264;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">16 on Y-</span></p>
<p style="top:255.0pt;left:526.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">BOCS) in OCD, compared</span></p>
<p style="top:158.0pt;left:445.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">No signi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cant differences</span></p>
<p style="top:158.0pt;left:454.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">between granisetron and</span></p>
<p style="top:158.0pt;left:463.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span></p>
<p style="top:105.2pt;left:541.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Continues</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">)</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">73</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:704.5pt;left:56.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Table 1.</span></p>
<p style="top:671.2pt;left:56.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(Continued)</span></p>
<p style="top:704.5pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Drug</span></p>
<p style="top:653.4pt;left:101.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Investigators,</span></p>
<p style="top:655.3pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">year (location)</span></p>
<p style="top:588.8pt;left:101.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Experimental</span></p>
<p style="top:577.9pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">design</span></p>
<p style="top:518.6pt;left:74.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Number, age</span></p>
<p style="top:527.8pt;left:83.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(years) and gender</span></p>
<p style="top:514.7pt;left:92.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of patients</span></p>
<p style="top:523.9pt;left:101.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receiving 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span></p>
<p style="top:515.8pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antagonists</span></p>
<p style="top:454.9pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Co-morbidities</span></p>
<p style="top:371.2pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Doses</span></p>
<p style="top:313.5pt;left:101.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Psychometric</span></p>
<p style="top:299.7pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tools</span></p>
<p style="top:221.6pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Results</span></p>
<p style="top:131.6pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Side effects</span></p>
<p style="top:255.0pt;left:128.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with 35% of placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:255.0pt;left:137.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:704.5pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:657.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2014 (Florence,</span></p>
<p style="top:657.0pt;left:164.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Italy)</span></p>
<p style="top:600.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">12-week</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt"> &#x2018;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">single-</span></p>
<p style="top:600.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">blind</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> (using blind</span></p>
<p style="top:600.0pt;left:164.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">rater to assess</span></p>
<p style="top:600.0pt;left:173.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">patient status)</span></p>
<p style="top:600.0pt;left:182.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">administration of</span></p>
<p style="top:600.0pt;left:191.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron to</span></p>
<p style="top:600.0pt;left:200.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment-resistant</span></p>
<p style="top:600.0pt;left:209.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients</span></p>
<p style="top:600.0pt;left:218.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">already treated with</span></p>
<p style="top:600.0pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antidepressants;</span></p>
<p style="top:600.0pt;left:236.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">another 4 weeks of</span></p>
<p style="top:600.0pt;left:245.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron</span></p>
<p style="top:600.0pt;left:254.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">discontinuation</span></p>
<p style="top:528.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">21 treatment-</span></p>
<p style="top:528.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">resistant (at least</span></p>
<p style="top:528.0pt;left:164.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">24 on the Y-BOCS</span></p>
<p style="top:528.0pt;left:173.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and 4 on the CGIs</span></p>
<p style="top:528.0pt;left:181.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">after</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">12-week</span></p>
<p style="top:528.0pt;left:191.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment with</span></p>
<p style="top:528.0pt;left:200.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">adequately dosed</span></p>
<p style="top:528.0pt;left:209.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">SSRIs) DSM-IV</span></p>
<p style="top:528.0pt;left:218.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients,</span></p>
<p style="top:528.0pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mean age 36.43 &#xb1;</span></p>
<p style="top:528.0pt;left:236.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">10.37, 10 men and</span></p>
<p style="top:528.0pt;left:245.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">11 women</span></p>
<p style="top:461.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Exclusion of</span></p>
<p style="top:461.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">current axis I</span></p>
<p style="top:461.0pt;left:164.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorders or past</span></p>
<p style="top:461.0pt;left:173.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">depressive episode</span></p>
<p style="top:461.0pt;left:182.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">prior to onset of</span></p>
<p style="top:461.0pt;left:191.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD, substance</span></p>
<p style="top:461.0pt;left:200.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">abuse, treatment</span></p>
<p style="top:461.0pt;left:209.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with other</span></p>
<p style="top:461.0pt;left:218.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">psychotropic</span></p>
<p style="top:461.0pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drugs, behavioural</span></p>
<p style="top:461.0pt;left:236.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">psychotherapy</span></p>
<p style="top:461.0pt;left:245.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and major physical</span></p>
<p style="top:461.0pt;left:254.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disease</span></p>
<p style="top:394.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Add-on 0.50 mg/</span></p>
<p style="top:394.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">day ondansetron for</span></p>
<p style="top:394.0pt;left:164.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">rst 2 weeks to</span></p>
<p style="top:394.0pt;left:173.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1 mg/day until the</span></p>
<p style="top:394.0pt;left:182.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">12th week (SSRIs</span></p>
<p style="top:394.0pt;left:191.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">unchanged)</span></p>
<p style="top:322.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS, CGI,</span></p>
<p style="top:322.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Drug Effect Scale</span></p>
<p style="top:255.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:255.0pt;left:154.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">augmentation</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> treatment</span></p>
<p style="top:255.0pt;left:163.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">response (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">25% Y-BOCS</span></p>
<p style="top:255.0pt;left:173.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drop from baseline and CGIi</span></p>
<p style="top:255.0pt;left:182.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1 or 2) in 57.14% of OCD</span></p>
<p style="top:255.0pt;left:191.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">patients; during</span></p>
<p style="top:255.0pt;left:200.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">discontinuation, relapse</span></p>
<p style="top:255.0pt;left:208.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">25% Y-BOCS increase</span></p>
<p style="top:255.0pt;left:218.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">from previous visit [last</span></p>
<p style="top:255.0pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2 weeks] and/or CGIi 6 or 7)</span></p>
<p style="top:255.0pt;left:236.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">occurred in 66.667% of</span></p>
<p style="top:255.0pt;left:245.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">responders</span></p>
<p style="top:158.0pt;left:146.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mild side effects, no</span></p>
<p style="top:158.0pt;left:155.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">discontinuation due to</span></p>
<p style="top:158.0pt;left:164.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">adverse events</span></p>
<p style="top:704.5pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span></p>
<p style="top:657.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.,</span></p>
<p style="top:657.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2014 (Tehran,</span></p>
<p style="top:657.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Iran)</span></p>
<p style="top:600.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">8-week double-</span></p>
<p style="top:600.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">blind ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:600.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine versus</span></p>
<p style="top:600.0pt;left:290.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:600.0pt;left:299.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:528.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">23 DSM-IV-TR</span></p>
<p style="top:528.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD patients,</span></p>
<p style="top:528.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mean age 36.2 &#xb1;</span></p>
<p style="top:526.5pt;left:290.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">6.9, 10 men and</span></p>
<p style="top:528.0pt;left:298.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">13 women,</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt"> &#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">21</span></p>
<p style="top:528.0pt;left:308.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS</span></p>
<p style="top:461.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Exclusion of axis I</span></p>
<p style="top:461.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorders,</span></p>
<p style="top:461.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">substance abuse in</span></p>
<p style="top:461.0pt;left:290.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the last 6 months,</span></p>
<p style="top:461.0pt;left:299.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">psychotherapy,</span></p>
<p style="top:461.0pt;left:308.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lactation,</span></p>
<p style="top:461.0pt;left:317.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">pregnancy and</span></p>
<p style="top:461.0pt;left:326.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">major medical</span></p>
<p style="top:461.0pt;left:335.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">condition</span></p>
<p style="top:394.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 4 mg</span></p>
<p style="top:394.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">q12h</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:394.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">100 mg/day</span></p>
<p style="top:394.0pt;left:290.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">combination for</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">rst</span></p>
<p style="top:394.0pt;left:299.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4 weeks, increased</span></p>
<p style="top:394.0pt;left:308.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">to 200 mg/day</span></p>
<p style="top:394.0pt;left:317.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">thereafter</span></p>
<p style="top:322.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Y-BOCS</span></p>
<p style="top:255.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:255.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">combination associated with</span></p>
<p style="top:255.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">48.48% drop in Y-BOCS,</span></p>
<p style="top:255.0pt;left:290.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compared with 30.27% of</span></p>
<p style="top:255.0pt;left:299.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine;</span></p>
<p style="top:255.0pt;left:308.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">furthermore, 86.37%</span></p>
<p style="top:255.0pt;left:316.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">complete response (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2265;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">35%</span></p>
<p style="top:255.0pt;left:326.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drop from baseline) versus</span></p>
<p style="top:255.0pt;left:335.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">31.8% placebo and 63.64%</span></p>
<p style="top:255.0pt;left:343.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">remission (</span><span style="font-family:AdvTT182ff89e+22,serif;font-size:8.0pt">&#x2264;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">16 on Y-</span></p>
<p style="top:255.0pt;left:353.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">BOCS) in OCD, compared</span></p>
<p style="top:255.0pt;left:362.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with 27.28% of placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:255.0pt;left:371.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine. Greater</span></p>
<p style="top:255.0pt;left:380.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">improvement with</span></p>
<p style="top:255.0pt;left:389.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:255.0pt;left:398.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">versus placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:255.0pt;left:407.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine signi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cant at</span></p>
<p style="top:255.0pt;left:416.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">weeks 4</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">6 on the Y-BOCS,</span></p>
<p style="top:255.0pt;left:425.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mainly due to the obsessive</span></p>
<p style="top:255.0pt;left:434.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">subscale</span></p>
<p style="top:158.0pt;left:263.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">No signi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cant differences</span></p>
<p style="top:158.0pt;left:272.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">between ondansetron and</span></p>
<p style="top:158.0pt;left:281.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo</span></p>
<p style="top:704.5pt;left:451.1pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Abbreviations</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. BDI, Beck Depression Inventory (Beck</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 1961); CGI, Clinical Global Impressions scale (Guy, 1976); CPRS-OC, Comprehensive Psychiatric Rating Scale, obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:704.5pt;left:460.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">subscale (Thor&#xe9;n</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 1980); GAD, Generalised Anxiety Disorder; HAM-A, Hamilton Rating Scale for Anxiety (Hamilton, 1959); HAM-D, Hamilton Rating Scale for Depression (Hamilton,</span></p>
<p style="top:704.5pt;left:469.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1960); i.v., intravenous; LOCF, last observation carried forward; MADRS, Montgomery</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">&#xc5;sberg Depression Scale (Montgomery and &#xc5;sberg, 1979); NOC, National Institute of Mental Health, Obses-</span></p>
<p style="top:704.5pt;left:478.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Compulsive Rating Scale (Insel</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 1983); OCD, obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder; PD, personality disorder; Y-BOCS, Yale</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Brown Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Compulsive Scale (Goodman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 1989).</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">74</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">between some models and possible utility in OCD. De-</span></p>
<p style="top:90.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">spite preclinical and pharmacological rationale for 5-</span></p>
<p style="top:102.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists in OCD treatment, only six clinical</span></p>
<p style="top:114.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">studies focused on this topic.</span></p>
<p style="top:126.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Ondansetron was</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst tested in healthy volunteers to</span></p>
<p style="top:138.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">assess the role of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors in anxiety behaviour</span></p>
<p style="top:150.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">triggered by mCPP. In single-dose administration,</span></p>
<p style="top:162.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">0.15mg/kg intravenous (i.v.) ondansetron pretreatment</span></p>
<p style="top:174.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">did not prevent the elicitation of anxiety by 0.08mg/kg</span></p>
<p style="top:186.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">i.v. mCPP but shortened the time needed for self-rated</span></p>
<p style="top:198.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">anxiety to return to its baseline levels, compared with</span></p>
<p style="top:210.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">double-blind placebo (Broocks</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1997). In a subse-</span></p>
<p style="top:222.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">quent study, the same randomised design and dosages</span></p>
<p style="top:234.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">were used in OCD patients, enriched by the addition</span></p>
<p style="top:246.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">placebo and placebo</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">placebo condi-</span></p>
<p style="top:258.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tions (Broocks</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998). Ondansetron did not affect</span></p>
<p style="top:270.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">anxiety ratings on its own and did not reverse the</span></p>
<p style="top:282.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">anxiogenic effect of mCPP, pointing to a difference in</span></p>
<p style="top:294.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor function between healthy volunteers</span></p>
<p style="top:306.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and OCD patients. The overall indication for the clini-</span></p>
<p style="top:318.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cal use of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists in OCD emerging</span></p>
<p style="top:330.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">from these pilot studies was not strong; however, after</span></p>
<p style="top:342.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">about 5years, an open-label trial followed (Hewlett</span></p>
<p style="top:354.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003). In another trial, ondansetron has been ad-</span></p>
<p style="top:366.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ministered to treatment-resistant OCD patients as an</span></p>
<p style="top:378.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">open-label add-on to SSRIs and antipsychotics (how-</span></p>
<p style="top:390.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ever, the trial was reported to be</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt"> &#x2018;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">single-blind</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> because</span></p>
<p style="top:402.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the rater was blinded as to patients</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> treatment condi-</span></p>
<p style="top:414.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion; Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009), whereas another study by</span></p>
<p style="top:426.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the same group used the same single-blind design on</span></p>
<p style="top:438.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">another set of patients, who were not taking anti-</span></p>
<p style="top:450.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">psychotics and who were observed longer, after with-</span></p>
<p style="top:462.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">drawing the add-on ondansetron (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014).</span></p>
<p style="top:474.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The other three recent trials that were carried out on</span></p>
<p style="top:486.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Iranian patients tested a combination of a 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> recep-</span></p>
<p style="top:498.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tor antagonist with an SSRI antidepressant, that is,</span></p>
<p style="top:510.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron and</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine (Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010),</span></p>
<p style="top:522.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron and</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uvoxamine (Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014) and</span></p>
<p style="top:534.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">granisetron and</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uvoxamine (Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012). Dura-</span></p>
<p style="top:546.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion of open monotherapy and combination studies was</span></p>
<p style="top:558.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">8weeks, whereas the most extended study was the one</span></p>
<p style="top:570.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">involving add-on in treatment-resistant OCD and the</span></p>
<p style="top:582.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">follow-up involving drug discontinuation. Trial results</span></p>
<p style="top:594.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">are summarised in Table 1.</span></p>
<p style="top:606.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">All patients received OCD DSM diagnoses. The early</span></p>
<p style="top:618.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mCPP challenge study used the DSM-III-R (American</span></p>
<p style="top:630.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Psychiatric Association, 1987), whereas the clinical</span></p>
<p style="top:642.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">studies used either the DSM-IV (American Psychiatric</span></p>
<p style="top:654.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Association, 1994) or the DSM-IV-TR (American Psy-</span></p>
<p style="top:666.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">chiatric Association, 2000). Cut-off for inclusion was</span></p>
<p style="top:678.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">16 on the Yale</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Brown Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Compulsive Scale</span></p>
<p style="top:690.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Y-BOCS) (Goodman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1989a, 1989b) in the open</span></p>
<p style="top:702.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study (Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003) and 21 in the three</span></p>
<p style="top:78.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">combination studies (Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010; Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:90.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2012; Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014; Table 1). Although not spec-</span></p>
<p style="top:102.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">i</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ed as an inclusion cut-off, the single-blind studies car-</span></p>
<p style="top:114.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ried out in treatment-resistant patients used a de</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nition</span></p>
<p style="top:126.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of treatment resistance of at least 20 Y-BOCS score after</span></p>
<p style="top:138.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">12weeks of adequate dosing of drugs that have proven</span></p>
<p style="top:150.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">anti-OCD ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy; hence, all patients in that study had</span></p>
<p style="top:162.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">scored at least 20 at baseline in the</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst of these studies</span></p>
<p style="top:174.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009), whereas in the second, the crite-</span></p>
<p style="top:186.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rion was even more restrictive, requiring both 24 on</span></p>
<p style="top:198.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the Y-BOCS and 4 on the Clinical Global Impressions</span></p>
<p style="top:210.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">scale (moderately ill) (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014).</span></p>
<p style="top:222.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Daily ondansetron doses ranged from 0.5 titrated to</span></p>
<p style="top:234.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">1mg in two studies (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009, 2014), to</span></p>
<p style="top:246.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">3mg in the open study (Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003), to 4mg</span></p>
<p style="top:258.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in one of the combination studies (Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010)</span></p>
<p style="top:270.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and 8mg in the other (Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014), whereas</span></p>
<p style="top:282.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2mg/day granisetron was used in the other combination</span></p>
<p style="top:294.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study (Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012). The range of ondansetron</span></p>
<p style="top:306.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">doses used in these studies (1</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">8mg/day) was lower than</span></p>
<p style="top:318.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the one used in schizophrenia (4</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">16mg/day; Bennett and</span></p>
<p style="top:330.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Vila, 2010). Because the antiemetic equivalence of the</span></p>
<p style="top:342.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">oral formulations of the two drugs is 1mg granisetron</span></p>
<p style="top:354.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to 32mg ondansetron (Fox-Geiman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2001), the</span></p>
<p style="top:366.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">dose of granisetron used by Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">. (2012) is rather</span></p>
<p style="top:378.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">high. The ondansetron dose is related to side effect</span></p>
<p style="top:390.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">appearance, as there were none (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009) or</span></p>
<p style="top:402.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">very few in the lowest-dose studies (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:414.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2014),</span></p>
<p style="top:414.2pt;left:339.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">whereas</span></p>
<p style="top:414.2pt;left:383.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">open</span></p>
<p style="top:414.2pt;left:413.6pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">administration</span></p>
<p style="top:414.2pt;left:483.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of</span></p>
<p style="top:414.2pt;left:502.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">3mg/day</span></p>
<p style="top:426.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron (Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003) was associated with</span></p>
<p style="top:438.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">18 adverse events in eight patients (ratio=2.25), with</span></p>
<p style="top:450.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">constipation dominating the scene (Table 2). Constipa-</span></p>
<p style="top:462.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion was not among the adverse events emerging with</span></p>
<p style="top:474.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine combination but did appear</span></p>
<p style="top:486.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">with the granisetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uvoxamine combination (Table 2);</span></p>
<p style="top:498.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">however, some adverse events in these three studies</span></p>
<p style="top:510.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">could be partly attributed to the respective SSRI. The</span></p>
<p style="top:522.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study that used the highest ondansetron dose in this series</span></p>
<p style="top:534.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014) reported the highest number of side</span></p>
<p style="top:546.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">effects among ondansetron-using studies, that is, 31,</span></p>
<p style="top:558.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">with nausea and headache as the most frequent. The</span></p>
<p style="top:570.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">granisetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uvoxamine study (Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012) re-</span></p>
<p style="top:582.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ported 45 adverse events in 20 patients (ratio=2.25),</span></p>
<p style="top:594.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">compared with 12 in 20 patients in the ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span></p>
<p style="top:606.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine study (ratio=0.6, i.e. the most favourable,</span></p>
<p style="top:618.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">but again dose equivalences and SSRI co-administration</span></p>
<p style="top:630.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">should be considered; Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010). Among</span></p>
<p style="top:642.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">side effects, constipation, headache and dry mouth pre-</span></p>
<p style="top:654.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">dominated, whereas sexual disorders/dysfunctions were</span></p>
<p style="top:666.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">found in the two combination studies involving co-</span></p>
<p style="top:678.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">administration of SSRIs; this was an expected effect</span></p>
<p style="top:690.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">for this class of antidepressants, so we believe that it</span></p>
<p style="top:702.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">is unlikely that they would represent a side effect of</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">75</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:558.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists, although interactions are</span></p>
<p style="top:570.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">possible; in fact, ondansetron and other 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span></p>
<p style="top:582.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">antagonists were shown to interfere with animal erectile</span></p>
<p style="top:594.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">activity in conjunction with other serotonergic and dopa-</span></p>
<p style="top:606.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">minergic mechanisms (Maeda</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1994, 1995; Lau</span></p>
<p style="top:618.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007). Overall, the adverse symptom pattern mim-</span></p>
<p style="top:630.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">icked the one described for patients with neoplastic</span></p>
<p style="top:642.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">diseases treated for chemotherapy-induced nausea, ex-</span></p>
<p style="top:654.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cept for headache being less common than constipation</span></p>
<p style="top:666.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Goodin and Cunningham, 2002). The event/patient</span></p>
<p style="top:678.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ratios found in oncological studies were 0.85 for</span></p>
<p style="top:690.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">32mg/day i.v. ondansetron and 0.77 for 2mg/day oral</span></p>
<p style="top:702.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">granisetron (Perez</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998). Generally, symptoms</span></p>
<p style="top:558.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">were not severe. A side effect constituted the reason for</span></p>
<p style="top:570.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study discontinuation only in one case of a patient treated</span></p>
<p style="top:582.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">with ondansetron+</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine and dropped out for severe</span></p>
<p style="top:594.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">headache (Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010). Despite the high rate of</span></p>
<p style="top:606.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">side effect occurrence, ondansetron and granisetron ap-</span></p>
<p style="top:618.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pear to be safe and well tolerated.</span></p>
<p style="top:630.2pt;left:327.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The two 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists employed in</span></p>
<p style="top:642.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">clinical studies of OCD were administered to a total</span></p>
<p style="top:654.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of 62 patients; no study involved more than 22 patients</span></p>
<p style="top:666.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to expose to ondansetron or granisetron, and no study</span></p>
<p style="top:678.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">used exactly the same design as others. When designs</span></p>
<p style="top:690.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">were similar (i.e. SSRI+5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonist), as</span></p>
<p style="top:702.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in the case of Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">. (2010), Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">. (2012),</span></p>
<p style="top:77.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Table 2.</span></p>
<p style="top:77.6pt;left:89.6pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Reported adverse events with 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> antagonist treatment: a summary of published studies</span></p>
<p style="top:95.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Study</span></p>
<p style="top:95.6pt;left:155.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Drug, dose &#xd7; duration (number of patients)</span></p>
<p style="top:95.6pt;left:361.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Adverse event</span></p>
<p style="top:95.6pt;left:470.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Number of reported events</span></p>
<p style="top:113.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 2009</span></p>
<p style="top:113.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 0.5</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 1 mg/day added on</span></p>
<p style="top:122.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antidepressants and/or</span></p>
<p style="top:131.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antipsychotics &#xd7; 12 weeks (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> = 14)</span></p>
<p style="top:113.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">None</span></p>
<p style="top:113.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">0</span></p>
<p style="top:140.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 2003</span></p>
<p style="top:140.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 3 mg/day &#xd7; 8 weeks (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> = 8)</span></p>
<p style="top:140.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Constipation</span></p>
<p style="top:140.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5</span></p>
<p style="top:149.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dry mouth</span></p>
<p style="top:149.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4</span></p>
<p style="top:158.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Headache</span></p>
<p style="top:158.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:167.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Worsened premenstrual dysphoria</span></p>
<p style="top:167.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:176.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Gastrointestinal upset</span></p>
<p style="top:176.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:185.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Chest discomfort</span></p>
<p style="top:185.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:194.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Urinary urgency</span></p>
<p style="top:194.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:203.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dizziness</span></p>
<p style="top:203.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:212.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Agitated depression</span></p>
<p style="top:212.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:221.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Bacterial cholecystitis</span></p>
<p style="top:221.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:230.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 2010</span></p>
<p style="top:230.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 4 mg/day +</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine 20 mg/</span></p>
<p style="top:239.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">day &#xd7; 8 weeks (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> = 20)</span></p>
<p style="top:230.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Sweating</span></p>
<p style="top:230.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:239.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Headache</span></p>
<p style="top:239.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:248.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Anxiety</span></p>
<p style="top:248.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:257.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Sexual dysfunction</span></p>
<p style="top:257.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:266.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Insomnia</span></p>
<p style="top:266.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:275.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Decreased appetite</span></p>
<p style="top:275.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:284.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Tremor</span></p>
<p style="top:284.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:293.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 2012</span></p>
<p style="top:293.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Granisetron 2 mg/day +</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:302.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">100</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 200 mg/day &#xd7; 8 weeks (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> = 20)</span></p>
<p style="top:293.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Drowsiness</span></p>
<p style="top:293.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5</span></p>
<p style="top:302.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dry mouth</span></p>
<p style="top:302.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5</span></p>
<p style="top:311.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Constipation</span></p>
<p style="top:311.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5</span></p>
<p style="top:320.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Nausea</span></p>
<p style="top:320.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5</span></p>
<p style="top:329.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dizziness</span></p>
<p style="top:329.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4</span></p>
<p style="top:338.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Nervousness</span></p>
<p style="top:338.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4</span></p>
<p style="top:347.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Decreased appetite</span></p>
<p style="top:347.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:356.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Sweating</span></p>
<p style="top:356.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:365.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fatigue</span></p>
<p style="top:365.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:374.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Diarrhoea</span></p>
<p style="top:374.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:383.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Itching</span></p>
<p style="top:383.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:392.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Sexual dysfunction</span></p>
<p style="top:392.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:401.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Muscle tension</span></p>
<p style="top:401.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:410.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 2014</span></p>
<p style="top:410.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 0.5</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 1 mg/day added on SSRI</span></p>
<p style="top:419.6pt;left:149.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antidepressants &#xd7; 12 weeks (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> = 21)</span></p>
<p style="top:410.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Constipation</span></p>
<p style="top:410.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:419.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Headache</span></p>
<p style="top:419.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:428.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dizziness</span></p>
<p style="top:428.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1</span></p>
<p style="top:437.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">., 2014</span></p>
<p style="top:437.6pt;left:149.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron 8 mg/day +</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine</span></p>
<p style="top:446.6pt;left:149.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">100</span><span style="font-family:AdvTT6120e2aa+21,serif;font-size:8.0pt"> &#x2192;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> 200 mg/day &#xd7; 8 weeks (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> = 23)</span></p>
<p style="top:437.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dizziness</span></p>
<p style="top:437.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">6</span></p>
<p style="top:446.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Headache</span></p>
<p style="top:446.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5</span></p>
<p style="top:455.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Constipation</span></p>
<p style="top:455.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4</span></p>
<p style="top:464.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Muscle cramp</span></p>
<p style="top:464.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4</span></p>
<p style="top:473.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Nervousness</span></p>
<p style="top:473.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4</span></p>
<p style="top:482.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dry mouth</span></p>
<p style="top:482.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:491.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Insomnia</span></p>
<p style="top:491.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">3</span></p>
<p style="top:500.6pt;left:330.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Diarrhoea</span></p>
<p style="top:500.6pt;left:511.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2</span></p>
<p style="top:517.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">In the lowest-dose study, no adverse events were reported. Intake of 2 mg daily granisetron was associated with the emergence of more adverse events than</span></p>
<p style="top:526.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4 mg daily ondansetron; however, these differences may re</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ect differences in SSRI-associated adverse events. In fact, differences between ondansetron and</span></p>
<p style="top:535.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo in these studies were not signi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cant.</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">76</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the drugs were different and doses were not compa-</span></p>
<p style="top:90.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rable (Table 1). Because of small sample sizes and</span></p>
<p style="top:102.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study design heterogeneity, these</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ndings should be</span></p>
<p style="top:114.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">interpreted with caution.</span></p>
<p style="top:126.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">In all</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ve ondansetron studies and in the granisetron</span></p>
<p style="top:138.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study, treatment for 8 or 12weeks was associated with</span></p>
<p style="top:150.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">important Y-BOCS score reductions. In the open study,</span></p>
<p style="top:162.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">a 28% drop from baseline was observed after 8weeks</span></p>
<p style="top:174.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003), whereas in the resistant OCD</span></p>
<p style="top:186.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">studies, mean Y-BOCS drop was 21.29% (Pallanti</span></p>
<p style="top:198.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009) and 27.2% (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014) after the</span></p>
<p style="top:210.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">addition of oral ondansetron solution. In the three</span></p>
<p style="top:222.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">placebo-controlled SSRI+5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonist</span></p>
<p style="top:234.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">combination studies, Y-BOCS score reduction ranged</span></p>
<p style="top:246.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">from slightly less than 50% (Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014) to</span></p>
<p style="top:258.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">more than 80% (Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010) for ondansetron</span></p>
<p style="top:270.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and 60% for granisetron (Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012), but the</span></p>
<p style="top:282.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">possible effect of co-administered SSRI should be</span></p>
<p style="top:294.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">taken into account also when considering improve-</span></p>
<p style="top:306.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ment. However, the combination of an SSRI with a</span></p>
<p style="top:318.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonist was paralleled by signi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-</span></p>
<p style="top:330.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cantly greater drops in Y-BOCS scores than the combi-</span></p>
<p style="top:342.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nation with a placebo (Table 1; Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010;</span></p>
<p style="top:354.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012; Heidari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014).</span></p>
<p style="top:366.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The only positive response predictor identi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ed by</span></p>
<p style="top:378.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">these studies was the patient having tic-like manner-</span></p>
<p style="top:390.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">isms, reported only by the initial open study (Hewlett</span></p>
<p style="top:402.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003). This has not been replicated by others.</span></p>
<p style="top:440.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">DISCUSSION</span></p>
<p style="top:457.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">What do preclinical data suggest about OCD and</span></p>
<p style="top:469.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> receptor antagonists and is this matched by</span></p>
<p style="top:481.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">animal OCD models?</span></p>
<p style="top:498.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The main animal OCD models do not imply a role for 5-</span></p>
<p style="top:510.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists (Fineberg</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2011; Albelda</span></p>
<p style="top:522.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and Joel, 2012a, 2012b). However, some of these</span></p>
<p style="top:534.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">models are compatible with a role of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span></p>
<p style="top:546.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in the pathophysiology of OCD (Barnes</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990;</span></p>
<p style="top:558.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Shankar</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2000).</span></p>
<p style="top:570.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Drug treatment of OCD currently involves adminis-</span></p>
<p style="top:582.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tering SSRIs or TCAs with high af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nity for the seroto-</span></p>
<p style="top:594.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nin transporter. The</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst reports of ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy of such a</span></p>
<p style="top:606.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">drug in OCD regarded clomipramine and appeared</span></p>
<p style="top:618.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">during the late 1960s to early 1970s; they were lacking</span></p>
<p style="top:630.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">any neurochemical pathophysiological connection (cf.</span></p>
<p style="top:642.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Marshall, 1971), and the rationale was purely empirical.</span></p>
<p style="top:654.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Despite progress in the development of animal models</span></p>
<p style="top:666.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and neurochemistry-based drug design, the approach</span></p>
<p style="top:678.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of drug treatment of OCD remained largely empirical</span></p>
<p style="top:690.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and did not follow the indications stemming from ani-</span></p>
<p style="top:702.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mal studies. For example, one of the</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst successful</span></p>
<p style="top:78.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">animal models of OCD, the spontaneous alternation par-</span></p>
<p style="top:90.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">adigm, appeared in the medical literature in 1991, sug-</span></p>
<p style="top:102.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">gesting that 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor stimulation could be</span></p>
<p style="top:114.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">related to increased obsessive-like behaviour (Yadin</span></p>
<p style="top:126.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1991). This would allow speculating that by de-</span></p>
<p style="top:138.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">creasing 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor activity, OCD symptoms</span></p>
<p style="top:150.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">may improve. However, the year before, it was reported</span></p>
<p style="top:162.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that buspirone, a partial 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> agonist</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">,</span></p>
<p style="top:174.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">bene</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tted patients with OCD when given as an add-on</span></p>
<p style="top:186.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine (Markovitz</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1990); this study had a</span></p>
<p style="top:198.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pharmacological rationale that was generally based on</span></p>
<p style="top:210.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">animal studies of anxiety disorders, but</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> not</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> of OCD;</span></p>
<p style="top:222.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">hence, it preceded the implementation of the animal</span></p>
<p style="top:234.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD model, and in fact, it went the opposite way.</span></p>
<p style="top:246.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">About the same time the OCD model was proposed, a</span></p>
<p style="top:258.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">study of OCD patients suggested that the SSRI</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxe-</span></p>
<p style="top:270.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tine induced a downregulation of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-related re-</span></p>
<p style="top:282.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sponses in the long term (Lesch</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1991), pointing</span></p>
<p style="top:294.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to the same direction of the model.</span></p>
<p style="top:306.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The spontaneous alternation behaviour may be dif-</span></p>
<p style="top:318.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ferently affected by drugs depending on the substance</span></p>
<p style="top:330.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">used to impair it. For example, if impaired alternation</span></p>
<p style="top:342.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">is elicited through the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> agonist 8-OH-DPAT,</span></p>
<p style="top:354.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> inhibitors or long-term downregulators may</span></p>
<p style="top:366.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">counteract it, whereas in the mCPP setting, it is</span></p>
<p style="top:378.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2C</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> inhibitors that restore it (Papakosta</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:390.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2013). Again, all this receptor speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">city identi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ed in</span></p>
<p style="top:402.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the laboratory found little correspondence in terms of</span></p>
<p style="top:414.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">new drug development and clinical trial application.</span></p>
<p style="top:426.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The subsequently developed canine acral lick der-</span></p>
<p style="top:438.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">matitis model of OCD was based on the observation</span></p>
<p style="top:450.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that a drug class (serotonin transporter inhibitors) with</span></p>
<p style="top:462.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">proven effectiveness in OCD reduced the licking</span></p>
<p style="top:474.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behaviour that was responsible for triggering dermati-</span></p>
<p style="top:486.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tis (Rapoport</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1992). This model, which was</span></p>
<p style="top:498.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pharmacologically based, has been used little thereaf-</span></p>
<p style="top:510.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ter and did not lead to the development of drugs to</span></p>
<p style="top:522.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">use as anti-OCD.</span></p>
<p style="top:534.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The quinpirole-induced checking behaviour model</span></p>
<p style="top:546.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of OCD (Szechtman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998) pointed to the in-</span></p>
<p style="top:558.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">volvement of dopamine activation in the elicitation of</span></p>
<p style="top:570.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD-related behaviour in the rat. This would suggest</span></p>
<p style="top:582.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that interventions aiming at reducing dopaminergic</span></p>
<p style="top:594.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">activity mediated through D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors could be useful</span></p>
<p style="top:606.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in OCD. However, subsequent experimentation in the</span></p>
<p style="top:618.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">context of this model suggested only the possible utility</span></p>
<p style="top:630.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of kappa-opioid receptor manipulation (Perreault</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:642.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2007) and helped in realising the fact that behavioural</span></p>
<p style="top:654.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and</span></p>
<p style="top:654.2pt;left:330.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">environmental</span></p>
<p style="top:654.2pt;left:405.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">changes</span></p>
<p style="top:654.2pt;left:452.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">may</span></p>
<p style="top:654.2pt;left:483.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">modify</span></p>
<p style="top:654.2pt;left:527.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the</span></p>
<p style="top:666.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">quinpirole-related response (Zadicario</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007)</span></p>
<p style="top:678.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">but did not lead to the development of new drugs. Fur-</span></p>
<p style="top:690.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">thermore, the quinpirole-induced OCD-like behaviour</span></p>
<p style="top:702.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">was reversed in deer mice by serotonin transporter</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">77</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">inhibitors (Korff</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2008). Moreover, clomipramine</span></p>
<p style="top:90.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">in vitro</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> inhibited dopamine receptor binding (Austin</span></p>
<p style="top:102.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1991), which validates the model, inasmuch as</span></p>
<p style="top:114.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">clomipramine has shown superior anti-OCD activity</span></p>
<p style="top:126.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">than other antidepressants (Ackerman and Greenland,</span></p>
<p style="top:138.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2002). One could argue that the rat psychostimulant</span></p>
<p style="top:150.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(amphetamine) model</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ts to schizophrenia or mania</span></p>
<p style="top:162.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and would not be suitable for OCD. On the other hand,</span></p>
<p style="top:174.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in the quinpirole-induced water contra-freeloading rat</span></p>
<p style="top:186.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">model of OCD, clomipramine, but not D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-binding anti-</span></p>
<p style="top:198.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">psychotics, reduced this behaviour (De Carolis</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:210.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2011). This speaks in favour of the aptness of the model</span></p>
<p style="top:222.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">for OCD but also reveals the complexity of animal</span></p>
<p style="top:234.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behaviour and neurotransmitter</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">neuromodulator inter-</span></p>
<p style="top:246.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">actions. A chemical is bound to induce certain changes</span></p>
<p style="top:258.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that may be of interest to facets of multiple disorders, but</span></p>
<p style="top:270.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the challenge then is to dissect those changes and attri-</span></p>
<p style="top:282.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">bute them correctly to theirappropriate frame/condition.</span></p>
<p style="top:294.2pt;left:64.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The identi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ed dopaminergic component of OCD</span></p>
<p style="top:306.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">prompted people to try dopamine antagonists as add-</span></p>
<p style="top:318.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ons in OCD. The use of neuroleptics in OCD dates back</span></p>
<p style="top:330.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to the mid-1950s, but results were not</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt"> &#x2018;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">impressive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span></p>
<p style="top:342.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Trethowan and Scott, 1955). Add-on/augmentation</span></p>
<p style="top:354.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">strategies with atypical antipsychotics were adopted</span></p>
<p style="top:366.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">since the</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst decade of this century (D</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Amico</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:378.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2003). A meta-analysis of randomised controlled trials</span></p>
<p style="top:390.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">found a modest increase in ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy for risperidone and</span></p>
<p style="top:402.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">quetiapine as add-on treatments, in the face of scanty</span></p>
<p style="top:414.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">available data (Komossa</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010), but other analyses</span></p>
<p style="top:426.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">found risperidone and haloperidol, but not quetiapine or</span></p>
<p style="top:438.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">olanzapine (Bloch</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2006; Skapinakis</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007),</span></p>
<p style="top:450.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to be effective, although the latter was more positive for</span></p>
<p style="top:462.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">olanzapine and quetiapine than the former (Skapinakis</span></p>
<p style="top:474.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007).</span></p>
<p style="top:486.2pt;left:64.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst genetic study of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> involvement in the</span></p>
<p style="top:498.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pathophysiology of OCD indicated a lack of involve-</span></p>
<p style="top:510.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ment of this receptor in early-onset OCD (M&#xf6;ssner</span></p>
<p style="top:522.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007), but another study showed an association</span></p>
<p style="top:534.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">between the c.256G-allele of the HTR3E variant</span></p>
<p style="top:546.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rs7627615 and the washing phenotype and another</span></p>
<p style="top:558.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">between the HTR3E c.256G/c.256G-genotype and</span></p>
<p style="top:570.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">impaired performance on neuropsychological tasks</span></p>
<p style="top:582.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pertaining to visual organisation (Lennertz</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:594.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2014). Animal models of psychiatric disorders do not</span></p>
<p style="top:606.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">propose the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor as a putative mediator of</span></p>
<p style="top:618.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD-like behaviours but rather advance its possible</span></p>
<p style="top:630.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">involvement in anxiety, psychosis and mood regulation;</span></p>
<p style="top:642.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">their possible indication in OCD stems from indirect ev-</span></p>
<p style="top:654.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">idence. For example, 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors in the posterior</span></p>
<p style="top:666.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">VTA mediate reinforcing properties of alcohol (Rodd</span></p>
<p style="top:678.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2007, 2008), which eventually leads to compul-</span></p>
<p style="top:690.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sion (Everitt and Robbins, 2005), so it is possible that</span></p>
<p style="top:702.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists reduce the reinforcing</span></p>
<p style="top:78.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">properties of compulsions, which make part of the clin-</span></p>
<p style="top:90.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ical picture of OCD. Microinfusion in this area of</span></p>
<p style="top:102.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">quinpirole blocked the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor agonist-induced</span></p>
<p style="top:114.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">reinforcing effect of alcohols in the preceding experi-</span></p>
<p style="top:126.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ments similarly to 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists, hence</span></p>
<p style="top:138.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pointing to an effect of these drugs on the activity of do-</span></p>
<p style="top:150.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">paminergic neurons in the posterior VTA, which would</span></p>
<p style="top:162.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mediate reinforcement with increased</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ring and would</span></p>
<p style="top:174.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">be slowed down by 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists and pre-</span></p>
<p style="top:186.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">synaptic,</span></p>
<p style="top:186.2pt;left:366.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">somatodendritic</span></p>
<p style="top:186.2pt;left:446.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2</span></p>
<p style="top:186.2pt;left:468.6pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">autoreceptors.</span></p>
<p style="top:186.2pt;left:539.5pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The</span></p>
<p style="top:198.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">quinpirole model of OCD would be at odds with the</span></p>
<p style="top:210.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">aforementioned effect, but it should be underlined that</span></p>
<p style="top:222.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the area where effects are obtained matters and that the</span></p>
<p style="top:234.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">same substances may have opposite effects when ad-</span></p>
<p style="top:246.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ministered in different areas. So quinpirole may enhance</span></p>
<p style="top:258.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">reinforcement when delivered to the nucleus accumbens</span></p>
<p style="top:270.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and reduce it when given in the VTA. Another example</span></p>
<p style="top:282.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of the importance of the area that regards the effects of 5-</span></p>
<p style="top:294.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors is that their activation in the accumbens</span></p>
<p style="top:306.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">potentiates terminal dopaminergic activation, whereas</span></p>
<p style="top:318.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in the dorsolateral prefrontal cortex, both dopamine</span></p>
<p style="top:330.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and serotonin act synergistically to inhibit cortical neu-</span></p>
<p style="top:342.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rons (Gobbi and Janiri, 1999). More recently, an inte-</span></p>
<p style="top:354.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">grated dopamine-5-HT interactive model has been</span></p>
<p style="top:366.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">proposed, according to which quinpirole enhances com-</span></p>
<p style="top:378.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pulsive checking by acting on dopaminergic behavioural</span></p>
<p style="top:390.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">drive, whereas 8-OH-DPAT maintains such checking by</span></p>
<p style="top:402.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">inhibiting the serotonergic setting off of this control cir-</span></p>
<p style="top:414.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cuit (Alkhatib</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2013).</span></p>
<p style="top:426.2pt;left:327.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">A simple 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> inhibition model of the therapeutic</span></p>
<p style="top:438.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">effect of drugs soothing the symptoms of OCD cannot</span></p>
<p style="top:450.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">account for what is observed in the clinical setting; for</span></p>
<p style="top:462.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">example, clozapine, despite its recognised competitive</span></p>
<p style="top:474.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">antagonism of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors (Rammes</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2004,</span></p>
<p style="top:486.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2009), may induce obsessive symptoms or trigger a</span></p>
<p style="top:498.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">full-blown OCD picture in about one-</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">fth to one-fourth</span></p>
<p style="top:510.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of patients with schizophrenia (Mukhopadhaya</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:522.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2009; Sa</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2009), but has shown anti-OCD activity</span></p>
<p style="top:534.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in one patient with schizophrenia and co-morbid OCD</span></p>
<p style="top:546.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">when added on aripiprazole (Peters and de Haan,</span></p>
<p style="top:558.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2009). The obsessive symptom triggering by clozapine</span></p>
<p style="top:570.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">has been attributed to its ability to block 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">2A/2C</span></p>
<p style="top:582.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">receptors (Schirmbeck and Zink, 2012) as well as to its</span></p>
<p style="top:594.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ability to interfere with 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptors (Ichikawa</span></p>
<p style="top:606.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2001; Kayahan</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2005), whereas it is possible</span></p>
<p style="top:618.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that its anti-OCD effect could be due in part to 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> re-</span></p>
<p style="top:630.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ceptor blockade. It should also be recalled that clozapine</span></p>
<p style="top:642.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">is an antagonist of muscarinic M1 and M3 receptors, but</span></p>
<p style="top:654.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">with high concentrations, it shifts to partial agonism</span></p>
<p style="top:666.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Olianas</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1999); should something similar occur</span></p>
<p style="top:678.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to serotonergic receptors, it could explain why OCD</span></p>
<p style="top:690.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">symptoms in clozapine-treated people occurred with</span></p>
<p style="top:702.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">high blood concentrations of the drug (Schirmbeck and</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">78</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Zink, 2012). The clue to interpret</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ndings is the speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">c</span></p>
<p style="top:90.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">localisation of receptors in the various areas and the</span></p>
<p style="top:102.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">timing of administration of the various drugs, but also</span></p>
<p style="top:114.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">patient biological variability.</span></p>
<p style="top:126.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Alternative mechanisms involve the glutamate sys-</span></p>
<p style="top:138.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tem in OCD. Most data involve the medial prefrontal</span></p>
<p style="top:150.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cortex (Fan</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010; Aoki</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012), pointing</span></p>
<p style="top:162.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">to impaired glutamatergic transmission there (Aoki</span></p>
<p style="top:174.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012) and in the cortico-striatal-thalamo-cortical</span></p>
<p style="top:186.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">circuit in OCD patients (Ting and Feng, 2008). This</span></p>
<p style="top:198.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">could be re</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ected in an increased glutamate wasting</span></p>
<p style="top:210.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in the cerebrospinal</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uid of OCD patients (Chakrabarty</span></p>
<p style="top:222.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2005). Animal data point to the possible utility of</span></p>
<p style="top:234.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-methyl-</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.8pt">D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">-aspartate (NMDA) glutamate receptor en-</span></p>
<p style="top:246.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">hancement in OCD (Albelda</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010), and interest-</span></p>
<p style="top:258.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ingly, 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists attenuate and granisetron</span></p>
<p style="top:270.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">enhances rat medial prefrontal NMDA responses</span></p>
<p style="top:282.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Liang</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998).</span></p>
<p style="top:294.2pt;left:49.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">In summary, despite recent progress, animal models</span></p>
<p style="top:306.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">currently mimic insuf</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ciently human conditions and</span></p>
<p style="top:318.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">are currently unlikely to address the increasingly re-</span></p>
<p style="top:330.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ported heterogeneity of OCD (Starcevic and Brakoulias,</span></p>
<p style="top:342.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2008;Nedeljkovic</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">etal</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,2009;Taylor,2011;Brakoulias,</span></p>
<p style="top:354.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2013). The evidence for using 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antago-</span></p>
<p style="top:366.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nists in OCD is piecemeal and does not adhere to indica-</span></p>
<p style="top:378.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tions derived from animal models of OCD. So, how is it</span></p>
<p style="top:390.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that investigators decided to try 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists in</span></p>
<p style="top:402.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD?</span></p>
<p style="top:421.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">What do clinical 5-HT</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> receptor antagonist studies say</span></p>
<p style="top:433.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">about their utility in OCD?</span></p>
<p style="top:450.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The idea to use serotonin 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor inhibitors in</span></p>
<p style="top:462.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD could have been justi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ed after the report that</span></p>
<p style="top:474.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron pretreatment enhanced the return of</span></p>
<p style="top:486.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mCPP-induced anxiety behaviour back to normal in</span></p>
<p style="top:498.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">healthy human volunteers (Broocks</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1997), but</span></p>
<p style="top:510.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">scarcely so after the report that OCD patients were</span></p>
<p style="top:522.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">not responsive at all to ondansetron pretreatment</span></p>
<p style="top:534.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">before mCPP challenge (Broocks</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1998). The</span></p>
<p style="top:546.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rationale that serotonin 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor inhibitors could</span></p>
<p style="top:558.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">lower mesolimbic dopaminergic hyperactivity led</span></p>
<p style="top:570.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">some investigators to use it in Tourette</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">s disorder</span></p>
<p style="top:582.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Toren</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1999, 2005), a neuroleptic-responsive</span></p>
<p style="top:594.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">disorder sharing high co-morbidity with OCD and</span></p>
<p style="top:606.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">some of its pathogenic mechanisms (McDougle</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:618.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">1993). Ondansetron 8mg titrated to 16</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">24mg/day</span></p>
<p style="top:630.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">monotherapy was accompanied by improved tics in</span></p>
<p style="top:642.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">four out of six Tourette patients with a trend towards</span></p>
<p style="top:654.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">improvement also on the Y-BOCS in those three who</span></p>
<p style="top:666.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">were co-morbid with OCD in one open study (Toren</span></p>
<p style="top:678.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 1999). However, a double-blind study versus</span></p>
<p style="top:690.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">placebo that followed 6years later showed tic improve-</span></p>
<p style="top:702.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ment on only one of the two scales used and no</span></p>
<p style="top:78.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">improvement on the Y-BOCS (Toren</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2005).</span></p>
<p style="top:90.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">These results point to 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists be-</span></p>
<p style="top:102.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ing active against tics, but not compulsions, in</span></p>
<p style="top:114.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Tourette</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">s disorder, thus questioning their utility in</span></p>
<p style="top:126.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD if used alone.</span></p>
<p style="top:138.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonist properties of olanzapine and</span></p>
<p style="top:150.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mirtazapine, which induced improvement in nausea in-</span></p>
<p style="top:162.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">duced by inappropriately high doses of</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uoxetine in</span></p>
<p style="top:174.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">one case of poor insight OCD (Fornaro and Martino,</span></p>
<p style="top:186.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2010), hardly constitute an indication for OCD. How-</span></p>
<p style="top:198.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ever, speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">c 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists may nonspeci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cally</span></p>
<p style="top:210.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">increase treatment adherence to SSRIs, which have as</span></p>
<p style="top:222.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">their principal side effects nausea and vomiting; this</span></p>
<p style="top:234.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">could indirectly facilitate the therapeutic effects of</span></p>
<p style="top:246.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">SSRIs. It should be noted that in one of the studies</span></p>
<p style="top:258.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">considered here (Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2012), nausea was one</span></p>
<p style="top:270.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of the observed side effects; however, patients were</span></p>
<p style="top:282.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">also</span></p>
<p style="top:282.2pt;left:328.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">taking</span></p>
<p style="top:282.2pt;left:365.4pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">100</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">200mg/day</span></p>
<p style="top:282.2pt;left:447.5pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">uvoxamine,</span></p>
<p style="top:282.2pt;left:514.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">which</span></p>
<p style="top:294.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">might have caused the side effect.</span></p>
<p style="top:306.2pt;left:312.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">rst published paper on 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists in</span></p>
<p style="top:318.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD (Hewlett</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2003) had as a rationale the fact</span></p>
<p style="top:330.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that increased serotonin in the synapse may bene</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">t</span></p>
<p style="top:342.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">OCD and that 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists were found to have</span></p>
<p style="top:354.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">anxiolytic properties, which is distant from the view</span></p>
<p style="top:366.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">that OCD is not a typical anxiety disorder. The second</span></p>
<p style="top:378.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">paper published was that of an add-on trial of</span></p>
<p style="top:390.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron in OCD and had a sound rationale, not</span></p>
<p style="top:402.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">bound to any animal model of OCD, but integrating</span></p>
<p style="top:414.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the</span></p>
<p style="top:414.2pt;left:324.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">serotonergic</span></p>
<p style="top:414.2pt;left:388.5pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and</span></p>
<p style="top:414.2pt;left:413.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">dopaminergic</span></p>
<p style="top:414.2pt;left:483.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">models</span></p>
<p style="top:414.2pt;left:524.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and</span></p>
<p style="top:426.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">incorporating data from animal studies and human</span></p>
<p style="top:438.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">neuronal activation patterns of the prefrontal cortex,</span></p>
<p style="top:450.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">providing a rationale not limited to the mesolimbic</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span></p>
<p style="top:462.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mesostriatal transmissions, but extending to the</span></p>
<p style="top:474.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">frontal cortex and exploiting the cutting off of the re-</span></p>
<p style="top:486.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">inforcing potential of the disorder (Pallanti</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:498.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2009). The rationale offered by the ondansetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span></p>
<p style="top:510.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">SSRI combination study was that ondansetron had</span></p>
<p style="top:522.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">worked as an add-on in the previous study and based</span></p>
<p style="top:534.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">on considerations of the localisation of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span></p>
<p style="top:546.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">receptors and their actions, not attributing the possible</span></p>
<p style="top:558.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">anti-OCD activity to central or peripheral actions</span></p>
<p style="top:570.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Soltani</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010). Finally, the granisetron</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">SSRI</span></p>
<p style="top:582.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">combination study used as a rationale the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span></p>
<p style="top:594.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">antagonist-induced reduction of reinforcement as well</span></p>
<p style="top:606.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">as clinical considerations, focusing on the VTA,</span></p>
<p style="top:618.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">which</span></p>
<p style="top:618.2pt;left:338.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">is</span></p>
<p style="top:618.2pt;left:355.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">the</span></p>
<p style="top:618.2pt;left:379.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">origin</span></p>
<p style="top:618.2pt;left:415.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of</span></p>
<p style="top:618.2pt;left:434.2pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">both</span></p>
<p style="top:618.2pt;left:463.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mesolimbic</span></p>
<p style="top:618.2pt;left:525.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and</span></p>
<p style="top:630.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mesocortical dopaminergic projections (Askari</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:642.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2012). All these studies were consistent in their</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nd-</span></p>
<p style="top:654.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ing some bene</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">t for patients who were treated with</span></p>
<p style="top:666.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists. Despite these effects not being</span></p>
<p style="top:678.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">impressive, some bene</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">t was obtained, and the two</span></p>
<p style="top:690.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">randomised,</span></p>
<p style="top:690.2pt;left:365.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">placebo-controlled trials showed an</span></p>
<p style="top:702.2pt;left:302.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">advantage of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists over placebo in</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">79</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">obtained rating scale-documented improvement. How-</span></p>
<p style="top:90.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ever, safety data (Table 2) are favourable.</span></p>
<p style="top:102.2pt;left:64.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">In summary, the studies heretofore reporting clinical</span></p>
<p style="top:114.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">utility of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists in OCD are insuf-</span></p>
<p style="top:126.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cient to document their ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cacy either as monother-</span></p>
<p style="top:138.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">apy or as add-on or in combination with other drugs.</span></p>
<p style="top:150.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">However, data collected to date are not inconsistent,</span></p>
<p style="top:162.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">as they all point to the same direction. The possible</span></p>
<p style="top:174.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">usefulness of an add-on administration is suggested</span></p>
<p style="top:186.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">by the fact that 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists and SSRIs have a</span></p>
<p style="top:198.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">synergistic anxiolytic/antidepressant effect in neuro</span></p>
<p style="top:210.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">behavioural rodent models (Gupta</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014). Inter-</span></p>
<p style="top:222.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">estingly, recently developed antidepressants with anti-</span></p>
<p style="top:234.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> properties like vortioxetine, which was active</span></p>
<p style="top:246.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">in a spontaneous alternation rodent paradigm (whereas</span></p>
<p style="top:258.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ondansetron was inactive; Gaarn du Jardin</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">.,</span></p>
<p style="top:270.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">2014), are currently being proposed as possible treat-</span></p>
<p style="top:282.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ment for OCD (Pizarro</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014).</span></p>
<p style="top:303.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt">Limitations of currently available studies</span></p>
<p style="top:320.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Beyond the already underlined limitations of study het-</span></p>
<p style="top:332.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">erogeneity and small sample size, the heretofore con-</span></p>
<p style="top:344.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ducted trials did not classify their OCD patients</span></p>
<p style="top:356.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">according to subtypes (Lochner</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2008), dimen-</span></p>
<p style="top:368.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sions (Storch</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010) or proposed speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ers</span></p>
<p style="top:380.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(Leckman</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2010). In the DSM-5, hoarding disor-</span></p>
<p style="top:392.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">der is not put inside OCD, but along body dysmorphic</span></p>
<p style="top:404.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">disorder, hair pulling, skin picking and other clinical en-</span></p>
<p style="top:416.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tities; it is put aside as one of the obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:11.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">compulsive</span></p>
<p style="top:428.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and related disorders (American Psychiatric Associa-</span></p>
<p style="top:440.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">tion, 2013). As clinical studies performed to date have</span></p>
<p style="top:452.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">been conducted without distinction between hoarding</span></p>
<p style="top:464.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">disorder and OCD, it is possible that some OCD results</span></p>
<p style="top:476.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">could be ascribed to hoarding disorder. It should be</span></p>
<p style="top:488.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">stressed that OCD and hoarding disorder appear to be bi-</span></p>
<p style="top:500.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ologically distinct (Tolin</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2014). There was a lack of</span></p>
<p style="top:512.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">randomised controlled trials, and the possible year-</span></p>
<p style="top:524.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">of-publication bias (Ackerman and Greenland, 2002)</span></p>
<p style="top:536.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cannot be set off, since similar time intervals were in-</span></p>
<p style="top:548.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">volved in the Ackerman and Greenland (2002) regression</span></p>
<p style="top:560.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">analysis and in this review. Furthermore, the trials con-</span></p>
<p style="top:572.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ducted with 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> receptor antagonists in OCD as previ-</span></p>
<p style="top:584.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ously conceptualised are too few to allow for clear-cut</span></p>
<p style="top:596.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">conclusions to be drawn. Despite results heretofore being</span></p>
<p style="top:608.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">scanty, because the American Psychiatric Association</span></p>
<p style="top:620.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">(2007) considers it as a third-line treatment for OCD, this</span></p>
<p style="top:632.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">class of drugs is worth considering for further studies to</span></p>
<p style="top:644.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">clarify its possible utility in the treatment of OCD.</span></p>
<p style="top:673.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">CONCLUSION</span></p>
<p style="top:690.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">The few clinical studies of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:7.8pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt"> antagonists in the</span></p>
<p style="top:702.2pt;left:54.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">treatment of OCD support a role of these drugs in</span></p>
<p style="top:78.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">inducing improvement, but the relatively small sample</span></p>
<p style="top:90.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sizes do not allow drawing of straightforward conclu-</span></p>
<p style="top:102.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sions. Their effects were claimed to occur also in mono-</span></p>
<p style="top:114.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">therapy, but we feel that in the presence of drug</span></p>
<p style="top:126.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">resistance, their use would be best exploited in add-</span></p>
<p style="top:138.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ons. Clinical studies suggest that the question should</span></p>
<p style="top:150.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">be more focused upon by animal studies, whose indi-</span></p>
<p style="top:162.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">cations have not been tested adequately in clinical</span></p>
<p style="top:174.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">studies as of now and did not lead to date to the deve-</span></p>
<p style="top:186.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">lopment of new medications for OCD. Animal</span></p>
<p style="top:198.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">research and human clinical research need to keep</span></p>
<p style="top:210.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">pace of one another and to reciprocally incorporate the</span></p>
<p style="top:222.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">issues arising from each one. Future studies should be</span></p>
<p style="top:234.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">able to distinguish between OCD proper and hoarding</span></p>
<p style="top:246.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">disorder, which is currently being investigated autono-</span></p>
<p style="top:258.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">mously in clinical trials (e.g. Rodriguez</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:11.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">., 2013;</span></p>
<p style="top:270.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Saxena and Sumner, 2014).</span></p>
<p style="top:309.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">FINANCIAL AND COMPETING INTERESTS</span></p>
<p style="top:321.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">DISCLOSURE</span></p>
<p style="top:338.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">In the past 3years, Stefano Ferracuti has participated in</span></p>
<p style="top:350.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">advisory boards for P</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">zer and Lilly and received</span></p>
<p style="top:362.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">honoraria</span></p>
<p style="top:362.2pt;left:367.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">from</span></p>
<p style="top:362.2pt;left:396.8pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Lilly,</span></p>
<p style="top:362.2pt;left:429.1pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Bristol-Myers, Sigma Tau,</span></p>
<p style="top:374.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Schering and P</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">zer; Paolo Girardi has received research</span></p>
<p style="top:386.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">support from Lilly and Janssen, has participated in Advi-</span></p>
<p style="top:398.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">sory Boards for Lilly, Organon, P</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">zer and Schering and</span></p>
<p style="top:410.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">received honoraria from Lilly and Organon; Roberto</span></p>
<p style="top:422.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Tatarelli has participated in Advisory Boards for</span></p>
<p style="top:434.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Schering, Servier and P</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">zer and received honoraria</span></p>
<p style="top:446.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">from</span></p>
<p style="top:446.2pt;left:347.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Schering,</span></p>
<p style="top:446.2pt;left:396.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Servier</span></p>
<p style="top:446.2pt;left:436.4pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">and</span></p>
<p style="top:446.2pt;left:460.9pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">P</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">zer.</span></p>
<p style="top:446.2pt;left:497.4pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Georgios</span></p>
<p style="top:446.2pt;left:545.7pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">D.</span></p>
<p style="top:458.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">Kotzalidis is the recipient of a Research Grant of the Ital-</span></p>
<p style="top:470.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ian Ministry of Education and University.</span></p>
<p style="top:482.2pt;left:327.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">All other authors of this paper have no relevant</span></p>
<p style="top:494.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">liations or</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nancial involvement with any orga-</span></p>
<p style="top:506.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nisation or entity with a</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nancial interest in or</span></p>
<p style="top:518.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">nancial con</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:11.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ict with the subject matter or materials</span></p>
<p style="top:530.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">discussed in the manuscript. This includes employ-</span></p>
<p style="top:542.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ment, consultancies, honoraria, stock ownership or</span></p>
<p style="top:554.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">options, expert testimony, grants or patents received</span></p>
<p style="top:566.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">or pending, or royalties.</span></p>
<p style="top:606.2pt;left:317.3pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">ACKNOWLEDGEMENTS</span></p>
<p style="top:626.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">We gratefully acknowledge the contribution of the Librar-</span></p>
<p style="top:637.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">ians of the School of Medicine and Psychology of Sapienza</span></p>
<p style="top:648.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">University, Drs Mimma Ariano, Felicia Proietti, Ales</span></p>
<p style="top:659.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">Casciaro, Teresa Prioreschi, Susanna Rospo and the late</span></p>
<p style="top:670.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">Tiziana Mattei, in helping us in localising relevant literature.</span></p>
<p style="top:681.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">Furthermore, we thank Ms Lucilla Martinelli for assistance</span></p>
<p style="top:692.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">during the preparation of the manuscript. Ethical standards</span></p>
<p style="top:703.0pt;left:317.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">were met in the writing of this paper.</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">80</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.2pt;left:39.0pt;line-height:11.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:11.0pt">REFERENCES</span></p>
<p style="top:96.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ackerman DL, Greenland S. 2002. Multivariate meta-analysis of controlled</span></p>
<p style="top:105.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drug studies for obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psychopharmacol</span></p>
<p style="top:114.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">22</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 309</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">317.</span></p>
<p style="top:123.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Albelda N, Joel D. 2012a. Animal models of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disor-</span></p>
<p style="top:132.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">der: exploring pharmacology and neural substrates.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neurosci Biobehav</span></p>
<p style="top:141.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Rev</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 36</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 47</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">63.</span></p>
<p style="top:150.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Albelda N, Joel D. 2012b. Current animal models of obsessive compulsive</span></p>
<p style="top:159.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder: an update.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neuroscience</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 211</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 83</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">106.</span></p>
<p style="top:168.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Albelda N, Bar-On N, Joel D. 2010. The role of NMDA receptors in the</span></p>
<p style="top:177.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">signal attenuation rat model of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Psycho-</span></p>
<p style="top:186.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">pharmacology (Berl)</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 210</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 13</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">24.</span></p>
<p style="top:195.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Alkhatib AH, Dvorkin-Gheva A, Szechtman H. 2013. Quinpirole and</span></p>
<p style="top:204.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">8-OH-DPAT induce compulsive checking behavior in male rats by acting</span></p>
<p style="top:213.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">on different functional parts of an OCD neurocircuit.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Behav Pharmacol</span></p>
<p style="top:222.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">24</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 65</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">73.</span></p>
<p style="top:231.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Allen L, Tejera C. 1994. Treatment of clozapine-induced obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:240.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive symptoms with sertraline.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Am J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 151</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1096</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1097.</span></p>
<p style="top:249.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">American Psychiatric Association. 1987. Diagnostic and Statistical Manual</span></p>
<p style="top:258.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of Mental Disorders, Third Edition</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2014;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Revised (DSM-III-R). American</span></p>
<p style="top:267.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Psychiatric Association: Washington, D.C.</span></p>
<p style="top:276.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">American Psychiatric Association. 1994. Diagnostic and Statistical Manual</span></p>
<p style="top:285.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of Mental Disorders, Fourth Edition (DSM-IV). American Psychiatric</span></p>
<p style="top:294.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Association: Washington, D.C.</span></p>
<p style="top:303.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">American Psychiatric Association. 2000. Diagnostic and Statistical Manual</span></p>
<p style="top:312.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of Mental Disorders, Fourth Edition</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2014;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Text Revision (DSM-IV-TR).</span></p>
<p style="top:321.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">American Psychiatric Association: Washington, D.C.</span></p>
<p style="top:330.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">American Psychiatric Association. 2007. Practice Guideline for the Treat-</span></p>
<p style="top:339.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ment of Patients with Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Compulsive Disorder. American</span></p>
<p style="top:348.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Psychiatric Association: Arlington, VA.</span></p>
<p style="top:357.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">American Psychiatric Association. 2013. Diagnostic and Statistical Manual</span></p>
<p style="top:366.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of Mental Disorders, 5th Edition (DSM-5). American Psychiatric Associ-</span></p>
<p style="top:375.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ation: Arlington, VA.</span></p>
<p style="top:384.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Aoki Y, Aoki A, Suwa H. 2012. Reduction of</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-acetylaspartate in the</span></p>
<p style="top:393.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">medial</span></p>
<p style="top:393.6pt;left:76.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">prefrontal</span></p>
<p style="top:393.6pt;left:114.5pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cortex</span></p>
<p style="top:393.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">correlated</span></p>
<p style="top:393.6pt;left:180.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with</span></p>
<p style="top:393.6pt;left:202.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">symptom</span></p>
<p style="top:393.6pt;left:239.4pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">severity</span></p>
<p style="top:402.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: meta-analyses of 1H-MRS studies.</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in</span></sup></p>
<p style="top:411.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Transl Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: e153.</span></p>
<p style="top:420.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Askari N, Moin M, Sanati M,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2012. Granisetron adjunct to</span></p>
<p style="top:429.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine for moderate to severe obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: a</span></p>
<p style="top:438.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">randomized, double-blind, placebo-controlled trial.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> CNS Drugs</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 26</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:447.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">883</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">892.</span></p>
<p style="top:456.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Austin LS, Lydiard RB, Ballenger JC,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1991. Dopamine blocking ac-</span></p>
<p style="top:465.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tivity of clomipramine in patients with obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span></p>
<p style="top:474.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 225</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">232.</span></p>
<p style="top:483.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Barnes JM, Costall B, Coughlan J,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1990. The effects of ondansetron, a</span></p>
<p style="top:492.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor antagonist, on cognition in rodents and primates.</span></p>
<p style="top:501.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Pharmacol Biochem Behav</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 35</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 955</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">962.</span></p>
<p style="top:510.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. 1961. An inventory</span></p>
<p style="top:519.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">for measuring depression.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 4</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 561</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">571.</span></p>
<p style="top:528.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Bennett AC, Vila TM. 2010. The role of ondansetron in the treatment of</span></p>
<p style="top:537.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">schizophrenia.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Ann Pharmacother</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 44</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1301</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1306.</span></p>
<p style="top:546.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Blier P, de Montigny C. 1998. Possible serotonergic mechanisms underly-</span></p>
<p style="top:555.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ing the antidepressant and anti-obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder responses.</span></p>
<p style="top:564.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 44</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 313</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">323.</span></p>
<p style="top:573.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB,</span></p>
<p style="top:582.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Leckman JF. 2006. A systematic review: antipsychotic augmentation</span></p>
<p style="top:591.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with treatment refractory obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Mol Psychiatry</span></p>
<p style="top:600.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 622</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">632.</span></p>
<p style="top:609.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Bloom FE, Morales M. 1998. The central 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor in CNS disorders.</span></p>
<p style="top:618.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Neurochem Res</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 23</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 653</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">659.</span></p>
<p style="top:627.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Blower PR. 1995. Differences in anti-emetic predictability amongst 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span></p>
<p style="top:636.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receptor antagonist drugs. In Radiation and the GI Tract, Dubois A, King</span></p>
<p style="top:645.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">GL, Livengood DR (eds). CRC Press Inc.: Boca Raton, FL, 37</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">49.</span></p>
<p style="top:654.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Brakoulias V. 2013. Diagnostic subtyping of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disor-</span></p>
<p style="top:663.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">der: have we got it all wrong?</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Aust N Z J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 47</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 23</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">25.</span></p>
<p style="top:672.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Broocks A, Briggs NC, Pigott TA,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1997. Behavioral, physiological</span></p>
<p style="top:681.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and neuroendocrine responses in healthy volunteers to m-chlorop</span></p>
<p style="top:690.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">henylpiperazine (m-CPP) with and without ondansetron pretreatment.</span></p>
<p style="top:699.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychopharmacology (Berl)</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 130</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 91</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">103.</span></p>
<p style="top:78.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Broocks A, Pigott TA, Hill JL,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1998. Acute intravenous administra-</span></p>
<p style="top:87.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tion of ondansetron and m-CPP, alone and in combination, in patients</span></p>
<p style="top:96.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">with obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder (OCD): behavioral and biological</span></p>
<p style="top:105.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">results.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Psychiatry Res</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 79</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 11</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">20.</span></p>
<p style="top:114.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB. 1988. Pharmacologi-</span></p>
<p style="top:123.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cal properties of GR3803 F, a novel antagonist at 5HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J</span></p>
<p style="top:132.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 94</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 397</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">412.</span></p>
<p style="top:141.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. 2005. Gluta-</span></p>
<p style="top:150.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">matergic</span></p>
<p style="top:150.6pt;left:346.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">dysfunction</span></p>
<p style="top:150.6pt;left:392.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in</span></p>
<p style="top:150.6pt;left:407.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD.</span></p>
<p style="top:150.6pt;left:434.5pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Neuropsychopharmacology</span></p>
<p style="top:150.6pt;left:530.9pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:159.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1735</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1740.</span></p>
<p style="top:168.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Chen J, Li Z, Pan H,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2001. Maintenance of serotonin in the intestinal</span></p>
<p style="top:177.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mucosa and ganglia of mice that lack the high af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nity serotonin trans-</span></p>
<p style="top:186.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">porter: abnormal intestinal motility and the expression of cation</span></p>
<p style="top:195.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">transporters.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 21</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 6348</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">6361.</span></p>
<p style="top:204.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Choi Y. 2009. Ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cacy of treatments for patients with obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:213.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: a systematic review.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Am Acad Nurse Pract</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 21</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:222.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">207</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">213.</span></p>
<p style="top:231.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Choi IS, Cho JH, Kim JT,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2007. Serotoninergic modulation of</span></p>
<p style="top:240.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">GABAergic synaptic transmission in developing rat CA3 pyramidal</span></p>
<p style="top:249.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">neurons.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Neurochem</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 103</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 2342</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2353.</span></p>
<p style="top:258.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Costall B, Naylor RJ. 1992. Anxiolytic potential of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor antago-</span></p>
<p style="top:267.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nists.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Pharmacol Toxicol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 70</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 157</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">162.</span></p>
<p style="top:276.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Costall B, Domeney AM, Naylor RJ, Tyers MB. 1987. Effects of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span></p>
<p style="top:285.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receptor antagonist, GR38032F, on raised dopaminergic activity in the</span></p>
<p style="top:294.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mesolimbic system of the rat and marmoset brain.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 92</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:303.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">881</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">894.</span></p>
<p style="top:312.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Costall B, Naylor RJ, Tyers MB. 1990. The psychopharmacology of 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span></p>
<p style="top:321.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receptors.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Pharmacol Ther</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 47</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 181</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">202.</span></p>
<p style="top:330.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">D</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Amico G, Cedro C, Muscatello MR,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2003. Olanzapine augmenta-</span></p>
<p style="top:339.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tion of paroxetine-refractory obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Prog</span></p>
<p style="top:348.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Neuropsychopharmacol Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 27</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 619</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">623.</span></p>
<p style="top:357.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">De Carolis L, Schepisi C, Milella MS, Nencini P. 2011. Clomipramine, but</span></p>
<p style="top:366.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">not haloperidol or aripiprazole, inhibits quinpirole-induced water</span></p>
<p style="top:375.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">contrafreeloading, a putative animal model of compulsive behavior.</span></p>
<p style="top:384.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychopharmacology (Berl)</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 218</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 749</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">759.</span></p>
<p style="top:393.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Del Casale A, Kotzalidis GD, Rapinesi C,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2011. Functional neuroim-</span></p>
<p style="top:402.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">aging in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neuropsychobiology</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 64</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 61</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">85.</span></p>
<p style="top:411.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Denys D, Zohar J, Westenberg HG. 2004. The role of dopamine in</span></p>
<p style="top:420.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: preclinical and clinical evidence.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin</span></p>
<p style="top:429.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 14</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 11</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">17.</span></p>
<p style="top:438.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Doucet E, Latr&#xe9;moli&#xe8;re A, Darmon M, Hamon M, Emerit MB. 2007.</span></p>
<p style="top:447.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Immunolabelling of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3B</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor subunit in the central and</span></p>
<p style="top:456.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">peripheral nervous systems in rodents.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Eur J Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 26</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 355</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">366.</span></p>
<p style="top:465.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Dougherty DD, Rauch SL, Jenike MA. 2004. Pharmacotherapy for</span></p>
<p style="top:474.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psychol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 60</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1195</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1202.</span></p>
<p style="top:483.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Drisdel RC, Sharp D, Henderson T, Hales TG, Green WN. 2008. High</span></p>
<p style="top:492.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nity binding of epibatidine to serotonin type 3 receptors.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Biol Chem</span></p>
<p style="top:501.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 9659</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">9665.</span></p>
<p style="top:510.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Edwards E, Hampton E, Ashby CR, Zhang J, Wang RY. 1996. 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-like</span></p>
<p style="top:519.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receptors in the rat medial prefrontal cortex: further pharmacological</span></p>
<p style="top:528.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">characterization.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Brain Res</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 733</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 21</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">30.</span></p>
<p style="top:537.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Eilam D, Szechtman H. 2005. Psychostimulant-induced behavior as an an-</span></p>
<p style="top:546.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">imal model of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: an ethological approach to</span></p>
<p style="top:555.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the form of compulsive rituals.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> CNS Spectr</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 10</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 191</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">202.</span></p>
<p style="top:564.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">El Mansari M, Blier P. 2006. Mechanisms of action of current and potential</span></p>
<p style="top:573.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">pharmacotherapies of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Prog Neurops</span></p>
<p style="top:582.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">ychopharmacol Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 362</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">373.</span></p>
<p style="top:591.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Everitt BJ, Robbins TW. 2005. Neural systems of reinforcement for drug</span></p>
<p style="top:600.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">addiction: from actions to habits to compulsion.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Nat Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 8</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:609.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1481</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1489.</span></p>
<p style="top:618.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Exley R, Cragg SJ. 2008. Presynaptic nicotinic receptors: a dynamic and di-</span></p>
<p style="top:627.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">verse cholinergic</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lter of striatal dopamine neurotransmission.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J</span></p>
<p style="top:636.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 153</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 283</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">297.</span></p>
<p style="top:645.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fan Q, Tan L, You C,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2010. Increased</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-acetylaspartate/creatine ratio</span></p>
<p style="top:654.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in</span></p>
<p style="top:654.6pt;left:322.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the</span></p>
<p style="top:654.6pt;left:339.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">medial</span></p>
<p style="top:654.6pt;left:367.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">prefrontal</span></p>
<p style="top:654.6pt;left:405.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cortex</span></p>
<p style="top:654.6pt;left:431.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">among</span></p>
<p style="top:654.6pt;left:459.6pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">unmedicated</span></p>
<p style="top:654.6pt;left:506.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:663.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder patients.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Psychiatry Clin Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 64</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 483</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">490.</span></p>
<p style="top:672.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fern&#xe1;ndez de C&#xf3;rdoba E, L&#xf3;pez-Ibor Ali&#xf1;o JJ. 1967. La monoclorimipramina</span></p>
<p style="top:681.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">en enfermos psiqui&#xe1;tricos resistentes a otros tratamientos (Clomipramine in</span></p>
<p style="top:690.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">psychiatric patients resistant to other treatments; in Spanish).</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Actas Luso</span></p>
<p style="top:699.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Esp Neurol Psiquiatr</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 26</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 119</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">147.</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">81</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ferr&#xe3;o YA, Diniz JB, Lopes AC, Shavitt RG, Greenberg B, Miguel E.</span></p>
<p style="top:87.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2007. Resistance and refractoriness in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span></p>
<p style="top:96.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Rev Bras Psiquiatr</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 29</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 66</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">76.</span></p>
<p style="top:105.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fineberg NA, Chamberlain SR, Hollander E, Boulougouris V, Robbins</span></p>
<p style="top:114.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">TW. 2011. Translational approaches to obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder:</span></p>
<p style="top:123.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">from animal models to clinical treatment.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 164</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:132.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1044</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1061.</span></p>
<p style="top:141.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. 2013. Pharmaco-</span></p>
<p style="top:150.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">therapy of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: evidence-based treatment and</span></p>
<p style="top:159.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">beyond.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Aust N Z J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 47</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 121</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">141.</span></p>
<p style="top:168.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fornaro M, Martino M. 2010. Adding 5-hydroxytryptamine receptor type 3</span></p>
<p style="top:177.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antagonists may reduce drug-induced nausea in poor insight obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:186.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive patients taking off-label doses of selective serotonin reuptake</span></p>
<p style="top:195.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">inhibitors: a 52-week follow-up case report.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Ann Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 9</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 39.</span></p>
<p style="top:204.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fox-Geiman MP, Fisher SG, Kiley K, Fletcher-Gonzalez D, Porter N,</span></p>
<p style="top:213.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Stiff P. 2001. Double-blind comparative trial of oral ondansetron ver-</span></p>
<p style="top:222.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sus oral granisetron versus IV ondansetron in the prevention of nausea</span></p>
<p style="top:231.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and vomiting associated with highly emetogenic preparative regimens</span></p>
<p style="top:240.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">prior to stem cell transplantation.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Biol Blood Marrow Transplant</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 7</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:249.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">596</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">603.</span></p>
<p style="top:258.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Fukushima T, Ohtsubo T, Tsuda M, Yanagawa Y, Hori Y. 2009. Facilita-</span></p>
<p style="top:267.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tory actions of serotonin type 3 receptors on GABAergic inhibitory syn-</span></p>
<p style="top:276.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">aptic transmission in the spinal super</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cial dorsal horn.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Neurophysiol</span></p>
<p style="top:285.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">102</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1459</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1471.</span></p>
<p style="top:294.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Gaarn du Jardin K, Jensen JB, Sanchez C, Pehrson AL. 2014. Vortioxetine</span></p>
<p style="top:303.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">dose-dependentlyreverses5-HTdepletion-inducedde</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">citsinspatialwork-</span></p>
<p style="top:312.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ing and object recognition memory: a potential role for 5-HT1A receptor</span></p>
<p style="top:321.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">agonism and 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor antagonism.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Eur Neuropsychopharmacol</span></p>
<p style="top:330.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">24</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 160</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">171.</span></p>
<p style="top:339.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Gobbi G, Janiri L. 1999. Clozapine blocks dopamine, 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> and 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> re-</span></p>
<p style="top:348.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sponses in the medial prefrontal cortex: an in vivo microiontophoretic</span></p>
<p style="top:357.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">study.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Eur Neuropsychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 10</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 43</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">49.</span></p>
<p style="top:366.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Goodin S, Cunningham R. 2002. 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-receptor antagonists for the treat-</span></p>
<p style="top:375.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ment of nausea and vomiting: a reappraisal of their side-effect pro</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">le.</span></p>
<p style="top:384.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Oncologist</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 7</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 424</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">436.</span></p>
<p style="top:393.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR,</span></p>
<p style="top:402.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Charney DS. 1989. Ef</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cacy of</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:411.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder. A double-blind comparison with placebo.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psychiatry</span></p>
<p style="top:420.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">46</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 36</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">44.</span></p>
<p style="top:429.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Goodman WK, Price LH, Rasmussen SA,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1989a. The Yale</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Brown</span></p>
<p style="top:438.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Obsessive Compulsive Scale. I. Development, use, and reliability.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch</span></p>
<p style="top:447.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 46</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1006</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1011.</span></p>
<p style="top:456.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Goodman WK, Price LH, Rasmussen SA,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1989b. The Yale</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Brown</span></p>
<p style="top:465.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Obsessive Compulsive Scale. II. Validity.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 46</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:474.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1012</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1016.</span></p>
<p style="top:483.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman</span></p>
<p style="top:492.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">JF. 1990. Beyond the serotonin hypothesis: a role for dopamine in some</span></p>
<p style="top:501.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">forms of obsessive compulsive disorder?</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 51</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(Suppl. 8):</span></p>
<p style="top:510.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">36</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">43; discussion 55</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">58.</span></p>
<p style="top:519.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y. 2014. Antidepressant</span></p>
<p style="top:528.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and</span></p>
<p style="top:528.6pt;left:80.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">anti-anxiety</span></p>
<p style="top:528.6pt;left:125.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">like</span></p>
<p style="top:528.6pt;left:143.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">effects</span></p>
<p style="top:528.6pt;left:171.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of</span></p>
<p style="top:528.6pt;left:185.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">4i</span></p>
<p style="top:528.6pt;left:198.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-(3-chloro-2-methylphenyl)</span></p>
<p style="top:537.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">quinoxalin-2-carboxamide), a novel 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor antagonist in acute</span></p>
<p style="top:546.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and chronic neurobehavioral rodent models.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Eur J Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 735</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 59</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">67.</span></p>
<p style="top:555.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2014;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Re-</span></p>
<p style="top:564.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">vised (DHEW Publ No ADM 76-338). US Department of Health, Educa-</span></p>
<p style="top:573.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tion, and Welfare, Public Health Service, Alcohol, Drug Abuse, and</span></p>
<p style="top:582.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mental Health Administration, NIMH Psychopharmacology Research</span></p>
<p style="top:591.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Branch, Division of Extramural Research Programs: Rockville, MD;</span></p>
<p style="top:600.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">218</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">222.</span></p>
<p style="top:609.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hamilton M. 1959. The assessment of anxiety states by rating.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Med</span></p>
<p style="top:618.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 32</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 50</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">55.</span></p>
<p style="top:627.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hamilton M. 1960. A rating scale for depression.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Neurol Neurosurg</span></p>
<p style="top:636.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 23</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 56</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">62.</span></p>
<p style="top:645.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hanna GL, Yuwiler A, Cantwell DP. 1991. Whole blood serotonin in</span></p>
<p style="top:654.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">juvenile obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 29</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 738</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">744.</span></p>
<p style="top:663.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hanna GL, Yuwiler A, Coates JK. 1995. Whole blood serotonin and disrup-</span></p>
<p style="top:672.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tive behaviors in juvenile obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Am Acad</span></p>
<p style="top:681.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Child Adolesc Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 34</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 28</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">35.</span></p>
<p style="top:690.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hasler W. 2009. Serotonin and the GI tract.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Curr Gastroenterol Rep</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 11</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:699.6pt;left:62.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">383</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">391.</span></p>
<p style="top:78.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Heidari M, Zarei M, Hosseini SM,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2014. Ondansetron or placebo in</span></p>
<p style="top:87.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the augmentation of</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine response over 8 weeks in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:96.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Int Clin Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 29</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 344</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">350.</span></p>
<p style="top:105.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hewlett WA, Trivedi BL, Zhang Z- J,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1999. Characterization of (</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">S</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">)-</span></p>
<p style="top:114.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">des-4amino-3-[</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">125</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">I]iodozacopride ([</span><sup><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">125</span></sup><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">I]DAIZAC), a selective high-</span></p>
<p style="top:123.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nity radioligand for 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Pharmacol Exp Ther</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 288</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:132.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">221</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">231.</span></p>
<p style="top:141.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hewlett WA, Schmid SP, Salomon RM. 2003. Pilot trial of ondansetron in</span></p>
<p style="top:150.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the treatment of 8 patients with obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin</span></p>
<p style="top:159.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 64</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1025</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1030.</span></p>
<p style="top:168.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hoffman KL. 2011. Animal models of obsessive compulsive disorder: re-</span></p>
<p style="top:177.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cent</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ndings and future directions.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Expert Opin Drug Discov</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 6</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:186.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">725</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">737.</span></p>
<p style="top:195.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Hollander E, DeCaria CM, Nitescu A,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1992. Serotonergic function in</span></p>
<p style="top:204.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder. Behavioral and neuroendocrine re-</span></p>
<p style="top:213.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sponses to oral m-chlorophenylpiperazine and fen</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uramine in patients</span></p>
<p style="top:222.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and healthy volunteers.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 49</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 21</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">28.</span></p>
<p style="top:231.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Huang J, Spier AD, Pickel VM. 2004. 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor subunits in the rat</span></p>
<p style="top:240.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">medial nucleus of the solitary tract: subcellular distribution and relation</span></p>
<p style="top:249.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">to the serotonin transporter.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Brain Res</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 1028</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 156</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">169.</span></p>
<p style="top:258.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Laughlin IA, Meltzer</span></p>
<p style="top:267.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">HY. 2001. 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">2A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> and D</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor blockade increases cortical DA re-</span></p>
<p style="top:276.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lease via 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor activation: a possible mechanism of atypical</span></p>
<p style="top:285.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antipsychotic-induced cortical dopamine release.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Neurochem</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 76</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:294.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1521</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1531.</span></p>
<p style="top:303.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Insel TR, Murphy DL, Cohen RC, Altermann I, Kilts C, Linnoila M. 1983.</span></p>
<p style="top:312.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">OCD: a double-blind trial of clomipramine and clorgyline.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen</span></p>
<p style="top:321.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 40</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 605</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">612.</span></p>
<p style="top:330.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Jenike MA, Buttolph L, Baer L, Ricciardi J, Holland A. 1989. Open trial of</span></p>
<p style="top:339.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Am J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 146</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:348.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">909</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">911.</span></p>
<p style="top:357.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Katz RJ, DeVeaugh-Geiss J, Landau P. 1990. Clomipramine in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:366.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 28</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 401</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">414.</span></p>
<p style="top:375.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Kayahan B, &#xd6;zt&#xfc;rk &#xd6;, Veznedaro</span><span style="font-family:AdvTT6120e2aa+01,serif;font-size:8.0pt">&#x11f;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lu B. 2005.</span><span style="font-family:AdvTT6120e2aa+01,serif;font-size:8.0pt"> &#x15e;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">izofrenide obsesif</span></p>
<p style="top:384.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">kompulsif belirtiler (Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive symptoms in schizophrenia;</span></p>
<p style="top:393.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in Turkish).</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Turk Psikiyatri Derg</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 16</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 205</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">215.</span></p>
<p style="top:402.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. 2010. Second-</span></p>
<p style="top:411.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">generation antipsychotics for obsessive compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Cochrane</span></p>
<p style="top:420.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Database Syst Rev</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> (</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">12</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">): CD008141.</span></p>
<p style="top:429.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Korff S, Stein DJ, Harvey BH. 2008. Stereotypic behaviour in the deer</span></p>
<p style="top:438.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mouse: pharmacological validation and relevance for obsessive compul-</span></p>
<p style="top:447.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sive</span></p>
<p style="top:447.6pt;left:344.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder.</span></p>
<p style="top:447.6pt;left:379.6pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Prog</span></p>
<p style="top:447.6pt;left:402.4pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Neuropsychopharmacol</span></p>
<p style="top:447.6pt;left:485.5pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Biol</span></p>
<p style="top:447.6pt;left:505.5pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Psychiatry</span></p>
<p style="top:447.6pt;left:546.1pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">32</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:456.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">348</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">355.</span></p>
<p style="top:465.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Lau DH, Thompson CS, Mumtaz FH, Morgan RJ, Mikhailidis DP. 2007.</span></p>
<p style="top:474.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Serotonin induces a biphasic response in rabbit cavernosal smooth mus-</span></p>
<p style="top:483.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cle: relevance to the erectile process.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Urol Int</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 79</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 255</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">261.</span></p>
<p style="top:492.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Leckman JF, Denys D, Simpson HB,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2010. Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:501.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder: a review of the diagnostic criteria and possible subtypes and</span></p>
<p style="top:510.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">dimensional speci</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ers for DSM-V.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Depress Anxiety</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 27</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 507</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">527.</span></p>
<p style="top:519.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Lennertz L, Wagner M, Grabe HJ,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2014. 5-HT3 receptor in</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uences</span></p>
<p style="top:528.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">the</span></p>
<p style="top:528.6pt;left:342.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">washing</span></p>
<p style="top:528.6pt;left:376.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">phenotype</span></p>
<p style="top:528.6pt;left:416.5pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and</span></p>
<p style="top:528.6pt;left:435.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">visual</span></p>
<p style="top:528.6pt;left:461.6pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">organization</span></p>
<p style="top:528.6pt;left:508.4pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">in</span></p>
<p style="top:528.6pt;left:522.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:537.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder supporting 5-HT3 receptor antagonists as novel</span></p>
<p style="top:546.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment option.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Eur Neuropsychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 24</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 86</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">94.</span></p>
<p style="top:555.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Lesch K-P, Hoh A, Schulte HM, Osterheider M, M&#xfc;ller T. 1991. Long-term</span></p>
<p style="top:564.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine treatment decreases 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">1A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor responsivity in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:573.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Psychopharmacology (Berl)</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 105</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 415</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">420.</span></p>
<p style="top:582.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Liang X, Arvanov VL, Wang RY. 1998. Inhibition of NMDA-receptor</span></p>
<p style="top:591.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mediated response in the rat medial prefrontal cortical pyramidal cells</span></p>
<p style="top:600.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">by the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor agonist SR 57227A and 5-HT: intracellular</span></p>
<p style="top:609.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">studies.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Synapse</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 29</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 257</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">268.</span></p>
<p style="top:618.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Lochner C, Hemmings SMJ, Kinnear CJ,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2008. Cluster analysis of</span></p>
<p style="top:627.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive symptomatology: identifying obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compu</span></p>
<p style="top:636.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lsive disorder subtypes.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Isr J Psychiatry Relat Sci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 45</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 164</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">176.</span></p>
<p style="top:645.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">L&#xf3;pez-Ibor JJ Jr. 1969. Intravenous perfusion of monochlorimipramine:</span></p>
<p style="top:654.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">technique and results. In The Present Status of Psychotropic Drugs. Pro-</span></p>
<p style="top:663.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ceedings of the VI International Congress of the Collegium Internationale</span></p>
<p style="top:672.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Neuro-psychopharmacologicum, Tarragona, Spain, 24</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">27 April, 1968,</span></p>
<p style="top:681.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Cerletti A, Bov&#xe9; FJ (eds). Excerpta Medica: Amsterdam.</span></p>
<p style="top:690.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Lucey JV, O</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Keane V, Butcher G, Clare AW, Dinan TG. 1992. Cortisol</span></p>
<p style="top:699.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and prolactin responses to d-fen</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uramine in non-depressed patients with</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">82</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: a comparison with depressed and</span></p>
<p style="top:87.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">healthy controls.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 161</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 517</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">521.</span></p>
<p style="top:96.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Maeda N, Matsuoka N, Yamaguchi I. 1994. Possible involvement of the</span></p>
<p style="top:105.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">septo-hippocampal cholinergic and raphe-hippocampal serotonergic acti-</span></p>
<p style="top:114.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">vations in the penile erection induced by fen</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uramine in rats.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Brain Res</span></p>
<p style="top:123.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">652</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 181</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">189.</span></p>
<p style="top:132.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Maeda N, Matsuoka N, Yamazaki M, Yamaguchi I. 1995. Involvement of</span></p>
<p style="top:141.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">raphe-hippocampal serotonergic and septo-hippocampal cholinergic</span></p>
<p style="top:150.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mechanisms in the penile erection induced by FR121196, a putative cog-</span></p>
<p style="top:159.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nitive enhancer.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Jpn J Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 68</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 85</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">94.</span></p>
<p style="top:168.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Markovitz PJ, Stagno SJ, Calabrese JR. 1990. Buspirone augmentation of</span></p>
<p style="top:177.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uoxetine in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Am J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 147</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:186.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">798</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">800.</span></p>
<p style="top:195.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Marshall WK. 1971. Treatment of obsessional illnesses and phobic anxiety</span></p>
<p style="top:204.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">states with clomipramine.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 119</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 467</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">468.</span></p>
<p style="top:213.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Martin KF, Hannon S, Phillips I, Heal DJ. 1992. Opposing roles for 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">1B</span></p>
<p style="top:222.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors in the control of 5-HT release in rat hippocampus</span></p>
<p style="top:231.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">in vivo</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 106</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 139</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">142.</span></p>
<p style="top:240.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">McDougle CJ, Goodman WK, Leckman JF, Price LH. 1993. The psycho-</span></p>
<p style="top:249.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">pharmacology of obsessive compulsive disorder. Implications for treat-</span></p>
<p style="top:258.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ment and pathogenesis.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Psychiatr Clin North Am</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 16</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 749</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">766.</span></p>
<p style="top:267.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price</span></p>
<p style="top:276.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">LH. 1994. Haloperidol addition in</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine-refractory obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:285.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder. A double-blind, placebo-controlled study in pa-</span></p>
<p style="top:294.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tients with and without tics.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 51</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 302</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">308.</span></p>
<p style="top:303.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000. A</span></p>
<p style="top:312.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">double-blind, placebo-controlled study of risperidone addition in seroto-</span></p>
<p style="top:321.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nin reuptake inhibitor-refractory obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch</span></p>
<p style="top:330.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 57</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 794</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">801.</span></p>
<p style="top:339.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Miyata K, Yamano M, Kamato T, Akuzawa S. 1995. Effect of serotonin (5-</span></p>
<p style="top:348.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">HT)</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-receptor antagonists YM060, YM114 (KAE-393), ondansetron and</span></p>
<p style="top:357.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">granisetron on 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">4</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors and gastric emptying in rodents.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Jpn J</span></p>
<p style="top:366.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 69</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 205</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">214.</span></p>
<p style="top:375.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Monteleone P, Catapano F, Di Martino S, Ferraro C, Maj M. 1997. Prolac-</span></p>
<p style="top:384.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tin response to</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> d</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">-fen</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uramine in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive patients, and out-</span></p>
<p style="top:393.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">come of</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">uvoxamine treatment.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 170</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 554</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">557.</span></p>
<p style="top:402.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Montgomery SA, &#xc5;sberg M. 1979. A new depression scale designed to be</span></p>
<p style="top:411.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sensitive to change.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Br J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 134</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 382</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">389.</span></p>
<p style="top:420.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Morales</span></p>
<p style="top:420.6pt;left:72.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">M,</span></p>
<p style="top:420.6pt;left:89.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Wang</span></p>
<p style="top:420.6pt;left:116.7pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">S-D.</span></p>
<p style="top:420.6pt;left:139.4pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2002.</span></p>
<p style="top:420.6pt;left:165.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Differential</span></p>
<p style="top:420.6pt;left:209.8pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">composition</span></p>
<p style="top:420.6pt;left:256.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of</span></p>
<p style="top:420.6pt;left:271.4pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">5-</span></p>
<p style="top:429.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">hydroxytryptamine</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors synthesized in the rat CNS and peripheral</span></p>
<p style="top:438.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nervous system.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 22</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 6732</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">6741.</span></p>
<p style="top:447.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Morales M, Battenberg E, Bloom FE. 1998. Distribution of neurons ex-</span></p>
<p style="top:456.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">pressing immunoreactivity for the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor subtype in the rat brain</span></p>
<p style="top:465.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and spinal cord.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Comp Neurol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 402</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 385</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">401.</span></p>
<p style="top:474.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">M&#xf6;ssner R, D&#xf6;ring N, Scherag A,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2007. Transmission disequilibrium</span></p>
<p style="top:483.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">analysis of the functional 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3A</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor variant C178T in early-onset</span></p>
<p style="top:492.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive compulsive-disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 21</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 833</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">836.</span></p>
<p style="top:501.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mukhopadhaya K, Krishnaiah R, Taye T,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2009. Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compul-</span></p>
<p style="top:510.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sive disorder in UK clozapine-treated schizophrenia and schizoaffective</span></p>
<p style="top:519.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder: a cause for clinical concern.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 23</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 6</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">13.</span></p>
<p style="top:528.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Mundo E, Bareggi SR, Pirola R, Bellodi L. 1999. Effect of acute intrave-</span></p>
<p style="top:537.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nous clomipramine and antiobsessional response to proserotonergic</span></p>
<p style="top:546.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drugs: is gender a predictive variable?</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 45</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 290</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">294.</span></p>
<p style="top:555.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Nedeljkovic M, Kyrios M, Moulding R,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2009. Differences in neuro-</span></p>
<p style="top:564.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">psychological performance between subtypes of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:573.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Aust N Z J Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 43</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 216</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">226.</span></p>
<p style="top:582.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Newth S, Rachman S. 2001. The concealment of obsessions.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Behav Res</span></p>
<p style="top:591.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Ther</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 39</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 457</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">464.</span></p>
<p style="top:600.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Norman TR, Apostolopoulos M, Burrows GD, Judd FK. 1994. Neuroendo-</span></p>
<p style="top:609.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">crine responses to single doses of buspirone in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:618.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Int Clin Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 9</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 89</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">94.</span></p>
<p style="top:627.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Olianas MC, Maullu C, Onali P. 1999. Mixed agonist</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">antagonist properties</span></p>
<p style="top:636.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of clozapine at different human cloned muscarinic receptor subtypes</span></p>
<p style="top:645.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">expressed in Chinese hamster ovary cells.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neuropsychopharmacology</span></p>
<p style="top:654.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">20</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 263</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">270.</span></p>
<p style="top:663.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ortega JE, Mendiguren A, Pineda J, Meana JJ. 2012. Regulation of central</span></p>
<p style="top:672.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">noradrenergic activity by 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptors located in the locus coeruleus</span></p>
<p style="top:681.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of the rat.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neuropharmacology</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 62</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 2472</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2479.</span></p>
<p style="top:690.6pt;left:39.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. 2009.</span></p>
<p style="top:699.6pt;left:47.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron augmentation in treatment-resistant obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:78.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder: a preliminary, single-blind, prospective study.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> CNS Drugs</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 23</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:87.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1047</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1055.</span></p>
<p style="top:96.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. 2014.</span></p>
<p style="top:105.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ondansetron augmentation in patients with obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disor-</span></p>
<p style="top:114.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">der who are inadequate responders to serotonin reuptake inhibitors: im-</span></p>
<p style="top:123.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">provement with treatment and worsening following discontinuation.</span></p>
<p style="top:132.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Eur Neuropsychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 24</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 375</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">380.</span></p>
<p style="top:141.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Papakosta VM, Kalogerakou S, Kontis D,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2013. 5-HT2C receptor in-</span></p>
<p style="top:150.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">volvement in the control of persistence in the reinforced spatial alterna-</span></p>
<p style="top:159.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tion animal model of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Behav Brain Res</span></p>
<p style="top:168.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">243</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 176</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">183.</span></p>
<p style="top:177.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Perez EA, Hesketh P, Sandbach J,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 1998. Comparison of single-dose</span></p>
<p style="top:186.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">oral granisetron versus intravenous ondansetron in the prevention of nau-</span></p>
<p style="top:195.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sea and vomiting induced by moderately emetogenic chemotherapy: a</span></p>
<p style="top:204.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">multicenter, double-blind, randomized parallel study.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Oncol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 16</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:213.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">754</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">760.</span></p>
<p style="top:222.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Perreault ML, Seeman P, Szechtman H. 2007. Kappa-opioid receptor stim-</span></p>
<p style="top:231.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ulation quickens pathogenesis of compulsive checking in the quinpirole</span></p>
<p style="top:240.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">sensitization model of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder (OCD).</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Behav</span></p>
<p style="top:249.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 121</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 976</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">991.</span></p>
<p style="top:258.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Peters B, de Haan L. 2009. Remission of schizophrenia psychosis and</span></p>
<p style="top:267.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">strong reduction of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder after adding cloza-</span></p>
<p style="top:276.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">pine to aripiprazole.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Prog Neuropsychopharmacol Biol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 33</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:285.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1576</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1577.</span></p>
<p style="top:294.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pizarro M, Fontenelle LF, Paravidino DC, Y&#xfc;cel M, Miguel EC, de</span></p>
<p style="top:303.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Menezes GB. 2014. An updated review of antidepressants with marked</span></p>
<p style="top:312.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">serotonergic effects in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Expert Opin</span></p>
<p style="top:321.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Pharmacother</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 15</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1391</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1401.</span></p>
<p style="top:330.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Pogarell O, Poepperl G, Mulert C,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2005. SERT and DAT availabilities</span></p>
<p style="top:339.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">under citalopram treatment in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder (OCD).</span></p>
<p style="top:348.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Eur Neuropsychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 15</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 521</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">524.</span></p>
<p style="top:357.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rabinowitz I, Baruch Y, Barak Y. 2008. High-dose escitalopram for the</span></p>
<p style="top:366.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Int Clin Psychopharmacol</span></p>
<p style="top:375.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">23</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 49</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">53.</span></p>
<p style="top:384.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ramasubbu R, Ravindran A, Lapierre Y. 2000. Serotonin and dopamine an-</span></p>
<p style="top:393.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tagonism in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: effect of atypical antipsy-</span></p>
<p style="top:402.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">chotic drugs.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Pharmacopsychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 33</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 236</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">238.</span></p>
<p style="top:411.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rammes G, Eisensamer B, Ferrari U,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2004. Antipsychotic drugs an-</span></p>
<p style="top:420.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tagonize human serotonin type 3 receptor currents in a noncompetitive</span></p>
<p style="top:429.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">manner.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Mol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 9</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 846</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">858, 818.</span></p>
<p style="top:438.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rammes G, Hosp C, Eisensamer B,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2009. Identi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">cation of a domain</span></p>
<p style="top:447.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">which affects kinetics and antagonistic potency of clozapine at 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> re-</span></p>
<p style="top:456.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ceptors.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> PLoS One</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 4</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: e6715.</span></p>
<p style="top:465.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rapoport JL, Ryland DH, Kriete M. 1992. Drug treatment of canine acral</span></p>
<p style="top:474.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lick. An animal model of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psy-</span></p>
<p style="top:483.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">chiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 49</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 517</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">521.</span></p>
<p style="top:492.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. 1995. Predictors of</span></p>
<p style="top:501.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">drug treatment response in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psy-</span></p>
<p style="top:510.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">chiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 56</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 368</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">373.</span></p>
<p style="top:519.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Remington G, Adams M. 1994. Risperidone and obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:528.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">symptoms.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 14</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 358</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">359.</span></p>
<p style="top:537.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rodd ZA, Gryszowka VE, Toalston JE,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2007. The reinforcing</span></p>
<p style="top:546.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">actions of a serotonin-3 receptor agonist within the ventral tegmen-</span></p>
<p style="top:555.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tal area: evidence for subregional and genetic differences and in-</span></p>
<p style="top:564.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">volvement</span></p>
<p style="top:564.6pt;left:350.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">of</span></p>
<p style="top:564.6pt;left:363.1pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">dopamine</span></p>
<p style="top:564.6pt;left:400.9pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">neurons.</span></p>
<p style="top:564.6pt;left:434.6pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">J</span></p>
<p style="top:564.6pt;left:444.6pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Pharmacol</span></p>
<p style="top:564.6pt;left:486.5pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Exp</span></p>
<p style="top:564.6pt;left:505.4pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Ther</span></p>
<p style="top:564.6pt;left:526.9pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">321</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:573.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1003</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1012.</span></p>
<p style="top:582.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rodd ZA, Oster SM, Ding ZM,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2008. The reinforcing properties of</span></p>
<p style="top:591.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">salsolinol in the ventral tegmental area: evidence for regional heterogene-</span></p>
<p style="top:600.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ity and the involvement of serotonin and dopamine.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Alcohol Clin Exp Res</span></p>
<p style="top:609.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">32</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 230</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">239.</span></p>
<p style="top:618.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Rodriguez CI, Bender J Jr, Morrison S, Mehendru R, Tolin D, Simpson HB.</span></p>
<p style="top:627.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">2013. Does extended release methylphenidate help adults with hoarding</span></p>
<p style="top:636.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">disorder? A case series.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 33</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 444</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">447.</span></p>
<p style="top:645.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ruscio AM, Stein DJ, Chiu WT, Kessler RC. 2010. The epidemiology of</span></p>
<p style="top:654.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder in the National Comorbidity Survey Rep-</span></p>
<p style="top:663.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">lication.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Mol Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 15</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 53</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">63.</span></p>
<p style="top:672.6pt;left:302.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Sa AR, Hounie AG, Sampaio AS, Arrais J, Miguel EC, Elkis H. 2009.</span></p>
<p style="top:681.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive symptoms and disorder in patients with schizo-</span></p>
<p style="top:690.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">phrenia treated with clozapine or haloperidol.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Compr Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 50</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:699.6pt;left:310.0pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">437</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">442.</span></p>
<p style="top:60.0pt;left:531.0pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">83</span></p>
<p style="top:60.0pt;left:234.3pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">5-ht</span><span style="font-family:AdvTT250121a6,serif;font-size:7.1pt">3</span><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt"> antagonists in ocd</span></p>
<p style="top:731.8pt;left:39.0pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:357.1pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:474.9pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>


<p style="top:78.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Saxena S, Sumner J. 2014. Venlafaxine extended-release treatment of</span></p>
<p style="top:87.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">hoarding disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Int Clin Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 29</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 266</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">273.</span></p>
<p style="top:96.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Schirmbeck F, Zink M. 2012. Clozapine-induced obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:105.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">symptoms in schizophrenia: a critical review.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Curr Neuropharmacol</span></p>
<p style="top:114.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">10</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 88</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">95.</span></p>
<p style="top:123.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Shankar RP, Karan RS, Handu SS, Bhargava VK. 2000. Effect of the 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span></p>
<p style="top:132.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receptor antagonist ondansetron on amphetamine-induced hyperactivity</span></p>
<p style="top:141.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and stereotypy in rats.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Indian J Physiol Pharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 44</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 355</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">358.</span></p>
<p style="top:150.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Skapinakis P, Papatheodorou T, Mavreas V. 2007. Antipsychotic augmen-</span></p>
<p style="top:159.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tation of serotonergic antidepressants in treatment-resistant obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:168.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: a meta-analysis of the randomized controlled trials.</span></p>
<p style="top:177.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Eur Neuropsychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 17</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 79</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">93.</span></p>
<p style="top:186.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. 2010.</span></p>
<p style="top:195.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">A double-blind, placebo-controlled pilot study of ondansetron for pa-</span></p>
<p style="top:204.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">tients with obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Hum Psychopharmacol</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 25</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:213.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">509</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">513.</span></p>
<p style="top:222.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Starcevic V, Brakoulias V. 2008. Symptom subtypes of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:231.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: are they relevant for treatment?</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Aust N Z J Psychi-</span></p>
<p style="top:240.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">atry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 42</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 651</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">661.</span></p>
<p style="top:249.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Stefa</span><span style="font-family:AdvTT6120e2aa+01,serif;font-size:8.0pt">&#x144;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ski R, Palejko W, Kostowski W, Pa</span><span style="font-family:AdvTT6120e2aa+01,serif;font-size:8.0pt">&#x142;&#x17a;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nik A. 1992. The comparison of</span></p>
<p style="top:258.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">benzodiazepine derivatives and serotonergic agonists and antagonists in</span></p>
<p style="top:267.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">two animal models of anxiety.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neuropharmacology</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 31</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1251</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1258.</span></p>
<p style="top:276.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Stein DJ, Fineberg NA, Bienvenu OJ,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2010. Should OCD be classi</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ed</span></p>
<p style="top:285.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">as an anxiety disorder in DSM-V?</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Depress Anxiety</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 27</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 495</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">506.</span></p>
<p style="top:294.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Storch EA, Larson MJ, Price LH, Rasmussen SA, Murphy TK, Goodman</span></p>
<p style="top:303.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">WK. 2010. Psychometric analysis of the Yale</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Brown Obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:312.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Compulsive Scale second edition symptom checklist.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Anxiety Disord</span></p>
<p style="top:321.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">24</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 650</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">656.</span></p>
<p style="top:330.6pt;left:54.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Szechtman H, Sulis W, Eilam D. 1998. Quinpirole induces compulsive</span></p>
<p style="top:339.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">checking behavior in rats: a potential animal model of obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:348.6pt;left:62.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder (OCD).</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Behav Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 112</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1475</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1485.</span></p>
<p style="top:78.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Taylor S. 2011. Early versus late onset obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder: ev-</span></p>
<p style="top:87.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">idence for distinct subtypes.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Clin Psychol Rev</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 31</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 1083</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1100.</span></p>
<p style="top:96.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Tecott LH, Maricq AV, Julius D. 1993. Nervous system distribution of the</span></p>
<p style="top:105.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">serotonin 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor mRNA.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Proc Natl Acad Sci U S A</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 90</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">:</span></p>
<p style="top:114.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1430</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">1434.</span></p>
<p style="top:123.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Thor&#xe9;n P, &#xc5;sberg M, Cronholm B. 1980. Clomipramine treatment of</span></p>
<p style="top:132.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Arch Gen Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 37</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 128</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">125.</span></p>
<p style="top:141.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Ting JT, Feng G. 2008. Glutamatergic synaptic dysfunction and obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:150.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Curr Chem Genomics</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 2</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 62</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">75.</span></p>
<p style="top:159.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Tolin DF, Witt ST, Stevens MC. 2014. Hoarding disorder and obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:168.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder show different patterns of neural activity during</span></p>
<p style="top:177.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">response inhibition.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Psychiatry Res</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 221</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 142</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">148.</span></p>
<p style="top:186.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Tonini M. 2005. 5-Hydroxytryptamine effect in the gut: the 3, 4 and 7</span></p>
<p style="top:195.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">receptors.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Neurogastroenterol Motil</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 17</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 637</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">642.</span></p>
<p style="top:204.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Toren P, Laor N, Cohen DJ, Wolmer L, Weizman A. 1999. Ondansetron</span></p>
<p style="top:213.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">treatment in patients with Tourette</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">s syndrome.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Int Clin Psychopharmacol</span></p>
<p style="top:222.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt">14</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 373</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">376.</span></p>
<p style="top:231.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Toren P, Weizman A, Ratner S, Cohen D, Laor N. 2005. Ondansetron treat-</span></p>
<p style="top:240.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ment in Tourette</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2019;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">s disorder: a 3-week, randomized, double-blind,</span></p>
<p style="top:249.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">placebo-controlled study.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> J Clin Psychiatry</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 66</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 499</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">503.</span></p>
<p style="top:258.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Trethowan WH, Scott PA. 1955. Chlorpromazine in obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive</span></p>
<p style="top:267.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">and allied disorders.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Lancet</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 268</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 781</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">785.</span></p>
<p style="top:276.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Yadin E, Friedman E, Bridger WH. 1991. Spontaneous alternation behav-</span></p>
<p style="top:285.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">ior: an animal model for obsessive</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive disorder?</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Pharmacol</span></p>
<p style="top:294.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt">Biochem Behav</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 40</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 311</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">315.</span></p>
<p style="top:303.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Zadicario P, Ronen S, Eilam D. 2007. Modulation of quinpirole-induced</span></p>
<p style="top:312.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">compulsive-like behavior in rats by environmental changes: implications</span></p>
<p style="top:321.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">for OCD rituals and for exploration and navigation.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> BMC Neurosci</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 8</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 23.</span></p>
<p style="top:330.6pt;left:317.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">Zhang ZJ, Schmidt DE, de Paulis T,</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">. 2001. Anxiolytic-like effects of</span></p>
<p style="top:339.6pt;left:325.3pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">DAIZAC, a selective high-af</span><span style="font-family:AdvTT6120e2aa+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">nity 5-HT</span><span style="font-family:AdvTT6120e2aa,serif;font-size:5.7pt">3</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt"> receptor antagonist, in the</span></p>
<p style="top:348.6pt;left:325.2pt;line-height:8.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">mouse elevated plus-maze.</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:8.0pt"> Pharmacol Biochem Behav</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:8.0pt"> 69</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">: 571</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:8.0pt">588.</span></p>
<p style="top:60.0pt;left:54.3pt;line-height:10.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:10.0pt">84</span></p>
<p style="top:60.0pt;left:272.5pt;line-height:10.0pt"><span style="font-family:AdvTT250121a6,serif;font-size:10.0pt">d. serata</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:7.0pt"> ET AL</span><span style="font-family:AdvTT50a2f13e.I,serif;font-size:10.0pt">.</span></p>
<p style="top:731.8pt;left:54.3pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">Copyright &#xa9; 2015 John Wiley &amp; Sons, Ltd.</span></p>
<p style="top:731.8pt;left:372.3pt;line-height:9.0pt"><span style="font-family:AdvTT50a2f13e.I,serif;font-size:9.0pt">Hum. Psychopharmacol Clin Exp</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt"> 2015;</span><span style="font-family:AdvTTb8864ccf.B,serif;font-size:9.0pt"> 30</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">: 70</span><span style="font-family:AdvTT6120e2aa+20,serif;font-size:9.0pt">&#x2013;</span><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">84</span></p>
<p style="top:741.8pt;left:490.2pt;line-height:9.0pt"><span style="font-family:AdvTT6120e2aa,serif;font-size:9.0pt">DOI: 10.1002/hup</span></p>
<p style="top:11.6pt;left:577.4pt;line-height:5.1pt"><span style="font-family:Times New Roman,serif;font-size:5.1pt"> 10991077, 2015, 2, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hup.2461 by Universit&#xe4;tsbibliothek Zuerich, Wiley Online Library on [27/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</span></p>

</div>
